

Talazoparib in Patients with Advanced Breast Cancer and

New England Journal of Medicine

379, 753-763

DOI: [10.1056/nejmoa1802905](https://doi.org/10.1056/nejmoa1802905)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Malignant external otitis. <i>Journal of Laryngology and Otology</i> , 1987, 101, 205-210.	0.4	62
3	Talazoparib: First Global Approval. <i>Drugs</i> , 2018, 78, 1939-1946.	4.9	106
4	Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19â€“23 October 2018. <i>Targeted Oncology</i> , 2018, 13, 673-677.	1.7	1
5	Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018, 10, 506.	1.7	40
6	Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. <i>Cancers</i> , 2018, 10, 487.	1.7	154
7	Development of PARP and Immune-Checkpoint Inhibitor Combinations. <i>Cancer Research</i> , 2018, 78, 6717-6725.	0.4	155
8	Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. <i>European Journal of Cancer</i> , 2018, 104, 160-168.	1.3	14
9	EMBRACing a new PARP inhibitor?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 655-655.	12.5	2
11	Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 773-785.	1.5	22
12	Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial. <i>Future Oncology</i> , 2019, 15, 2327-2335.	1.1	7
13	The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?. <i>Cancers</i> , 2019, 11, 1126.	1.7	90
15	<p>Triple-negative breast cancer: current perspective on the evolving therapeutic landscape</p>. <i>International Journal of Women's Health</i> , 2019, Volume 11, 431-437.	1.1	117
16	Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). <i>Breast Cancer Research and Treatment</i> , 2019, 178, 367-377.	1.1	3
17	Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2019, 8, 860.	1.8	34
18	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019, 30, 1541-1557.	0.6	464
19	Leveraging Clinical Tumor-Profilng Programs to Achieve Comprehensive Germline-Inclusive Precision Cancer Medicine. <i>JCO Precision Oncology</i> , 2019, 3, 1-3.	1.5	6
20	Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 759.	1.3	18
21	Site-specific analysis of the Asp- and Glu-ADP-ribosylated proteome by quantitative mass spectrometry. <i>Methods in Enzymology</i> , 2019, 626, 301-321.	0.4	9

#	ARTICLE	IF	CITATIONS
23	Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz005.	0.4	9
24	<p>Evidence to date: talazoparib in the treatment of breast cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5177-5187.	1.0	30
25	Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 151-159.	1.1	17
26	Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3390.	1.8	48
27	APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 309.	3.5	28
29	Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. <i>Case Reports in Oncology</i> , 2019, 12, 494-499.	0.3	5
30	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
31	Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3100.	1.8	32
32	Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 68.	1.3	9
33	Advances in Targeted Therapies for Triple-Negative Breast Cancer. <i>Drugs</i> , 2019, 79, 1217-1230.	4.9	71
34	Targeting DNA repair in breast cancer. <i>Breast</i> , 2019, 47, 33-42.	0.9	11
35	Treating HR+/HER2 [~] breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	1.1	29
36	PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2063-2073.	1.9	38
37	PARP Inhibition in Cancer: An Update on Clinical Development. <i>Targeted Oncology</i> , 2019, 14, 657-679.	1.7	133
38	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 34.	2.3	55
39	Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 341.	0.8	39
40	Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. <i>Cancer Cell</i> , 2019, 36, 545-558.e7.	7.7	176
41	ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1899-1908.	1.9	52

#	ARTICLE	IF	CITATIONS
42	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 119.	2.2	21
43	A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. <i>Theranostics</i> , 2019, 9, 6224-6238.	4.6	41
44	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3484-3492.	0.8	30
45	Mapping genetic interactions in cancer: a road to rational combination therapies. <i>Genome Medicine</i> , 2019, 11, 62.	3.6	16
46	Breast Cancer Metastasis and Drug Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	38
47	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	1.3	75
48	Pathogenic Germline Variants in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1506.	3.4	10
49	Emerging Novel Therapeutics in Triple-Negative Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 377-399.	0.8	23
50	Available and emerging molecular markers in the clinical management of breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 919-928.	1.5	9
51	Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. <i>Breast Cancer Research</i> , 2019, 21, 107.	2.2	51
52	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 247-255.	0.8	32
53	Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. <i>PLoS ONE</i> , 2019, 14, e0222358.	1.1	35
54	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 698-712.	0.4	69
55	Positron-Emission Tomographic Imaging of a Fluorine 18â€“Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patientâ€“Derived Xenografts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1743-1752.	0.5	14
56	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019, 5, 66.	18.1	1,620
57	Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. <i>BMC Cancer</i> , 2019, 19, 901.	1.1	33
58	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 288.	3.8	2,785
59	Whole genome sequencing of breast cancer. <i>Apmis</i> , 2019, 127, 303-315.	0.9	23

#	ARTICLE	IF	CITATIONS
60	Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2019, 30, 365-373.	0.6	106
61	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. <i>Annals of Oncology</i> , 2019, 30, 558-566.	0.6	493
62	Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 12-17.	0.9	7
63	Chlorambucil targets $\text{BRCA}1/2$ -deficient tumours and counteracts PARP inhibitor resistance. <i>EMBO Molecular Medicine</i> , 2019, 11, e9982.	3.3	26
64	Race, breast cancer, and prognosis: Where biology is queen?. <i>Cancer</i> , 2019, 125, 3104-3106.	2.0	1
65	<i>BRCA</i> Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. <i>Journal of Cancer</i> , 2019, 10, 2109-2127.	1.2	125
66	Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers. <i>Current Genetic Medicine Reports</i> , 2019, 7, 116-123.	1.9	0
67	A decade of clinical development of PARP inhibitors in perspective. <i>Annals of Oncology</i> , 2019, 30, 1437-1447.	0.6	437
68	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. <i>ESMO Open</i> , 2019, 4, e000480.	2.0	47
69	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 167-173.	0.9	9
70	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 605-617.	0.8	28
71	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. <i>Journal of Oncology</i> , 2019, 1-14.	0.6	18
72	Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 383-393.	1.1	12
73	Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model. <i>Frontiers in Oncology</i> , 2019, 9, 353.	1.3	15
75	Therapeutic innovations in breast cancer. <i>Presse Medicale</i> , 2019, 48, 1131-1137.	0.8	5
76	State of art of advanced triple negative breast cancer. <i>Breast Journal</i> , 2019, 25, 967-970.	0.4	25
77	Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 470-482.	0.8	26
78	Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 589-601.	1.1	8

#	ARTICLE	IF	CITATIONS
79	Immune Checkpoint and Poly(ADP-ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers. <i>JAMA Oncology</i> , 2019, 5, 1103.	3.4	2
80	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1132.	3.4	285
81	Rising and Falling Trends in the Use of Chemotherapy and Targeted Therapy Near the End of Life in Older Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1721-1731.	0.8	23
82	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. , 2019, 201, 94-102.		106
83	Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e8-e21.	1.8	22
84	The DNA Damaging Revolution: PARP Inhibitors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 185-195.	1.8	144
85	Molecular Testing in Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e1-e7.	1.8	27
86	Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 61-74.	1.8	41
87	PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells. <i>Frontiers in Physiology</i> , 2019, 10, 538.	1.3	16
88	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019, 15, 1951-1961.	1.1	58
89	Next-generation sequencing of <i>BRCA1</i> and <i>BRCA2</i> genes for rapid detection of germline mutations in hereditary breast/ovarian cancer. <i>PeerJ</i> , 2019, 7, e6661.	0.9	21
90	PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 722-737.	7.7	433
91	Luminal Metastatic Breast Cancer. <i>Breast Care</i> , 2019, 14, 99-101.	0.8	1
92	Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5330-5357.	2.9	26
93	Targeting the PI3-kinase pathway in triple-negative breast cancer. <i>Annals of Oncology</i> , 2019, 30, 1051-1060.	0.6	180
94	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2257-2269.	0.8	135
96	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1012-1019.	1.3	2
97	Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?. <i>Stem Cell Investigation</i> , 2019, 6, 4-4.	1.3	1

#	ARTICLE	IF	CITATIONS
98	A Phase 1 Mass Balance Study of ¹⁴ C-Labeled Talazoparib in Patients With Advanced Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1195-1203.	1.0	17
99	BRCA Testing Dichotomy in Saudi Arabia. <i>Journal of Global Oncology</i> , 2019, 5, 1-2.	0.5	0
100	Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 2019: personalised treatments for patients with early breast cancer. <i>Ecancermedalscience</i> , 2019, 13, 924.	0.6	19
101	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. <i>Biochemical Pharmacology</i> , 2019, 167, 133-148.	2.0	19
102	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
103	Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib. <i>Future Oncology</i> , 2019, 15, 1707-1715.	1.1	27
104	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	0.8	9
105	Using clinical genomic sequencing to guide personalized cancer therapy in China. <i>Personalized Medicine</i> , 2019, 16, 287-299.	0.8	2
106	Systemic Therapy of Central Nervous System Metastases of Breast Cancer. <i>Current Oncology Reports</i> , 2019, 21, 49.	1.8	26
107	Dissecting PARP inhibitor resistance with functional genomics. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 55-63.	1.5	22
108	Subcellular compartmentalization of NAD ⁺ and its role in cancer: A sereneNADE of metabolic melodies. , 2019, 200, 27-41.		53
109	Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 1305-1315.	0.8	266
110	<p><p>A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2321-2337.	0.9	83
111	Prevalence of germline variants in inflammatory breast cancer. <i>Cancer</i> , 2019, 125, 2194-2202.	2.0	14
112	Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. <i>Cancer Biology and Therapy</i> , 2019, 20, 1035-1045.	1.5	20
113	PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. <i>Journal of Clinical Medicine</i> , 2019, 8, 435.	1.0	106
114	Genetics of Familial and Sporadic Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 2041-2055.	0.6	52
115	Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. <i>Cancer Letters</i> , 2019, 454, 171-178.	3.2	14

#	ARTICLE	IF	CITATIONS
116	Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100121.	0.7	11
117	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 67-75.	0.9	16
118	PARP Inhibitors: Extending Benefit Beyond <i>BRCA</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 3759-3771.	3.2	265
119	Major clinical research advances in gynecologic cancer in 2018. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e18.	1.0	29
120	Therapeutic implications of germline genetic findings in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 386-396.	12.5	39
122	How I treat metastatic triple-negative breast cancer. <i>ESMO Open</i> , 2019, 4, e000504.	2.0	59
124	Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response. <i>Molecular Cancer Research</i> , 2020, 18, 253-263.	1.5	19
125	Advances and perspectives of PARP inhibitors. <i>Experimental Hematology and Oncology</i> , 2019, 8, 29.	2.0	81
127	Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	1.0	15
128	Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors. <i>Anti-Cancer Drugs</i> , 2019, 30, 523-532.	0.7	8
129	Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. <i>Breast Cancer Research</i> , 2019, 21, 143.	2.2	80
130	Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 247-255.	1.1	7
131	Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification. <i>Cancers</i> , 2019, 11, 1864.	1.7	5
132	Targeted Therapies for Triple-Negative Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 82.	1.3	237
133	Immunotherapy in Triple-Negative Breast Cancer: Present and Future. <i>Current Breast Cancer Reports</i> , 2019, 11, 259-271.	0.5	22
135	Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1309-1319.	0.8	11
136	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. <i>Cancers</i> , 2019, 11, 1980.	1.7	29
137	Hype or hope? The strange case of platinum salts™ renaissance in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 1005-1008.	1.1	2

#	ARTICLE	IF	CITATIONS
138	Practical Cancer Genetics and Genomics in Women's Health. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 687-699.	0.6	1
139	Current role of poly(ADP-ribose) polymerase inhibitors. <i>Current Opinion in Oncology</i> , 2019, 31, 394-403.	1.1	2
140	Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis. <i>Npj Breast Cancer</i> , 2019, 5, 46.	2.3	26
142	Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	0
143	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	14
144	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). <i>Clinical Cancer Research</i> , 2019, 25, 2717-2724.	3.2	102
145	Exploring and comparing adverse events between PARP inhibitors. <i>Lancet Oncology</i> , The, 2019, 20, e15-e28.	5.1	287
146	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019, 30, 405-411.	0.6	419
147	Atezolizumab for the treatment of triple-negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1-5.	1.9	78
148	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019, 30, 397-404.	0.6	538
149	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer: an European consensus statement and expert recommendations. <i>European Journal of Cancer</i> , 2019, 106, 54-60.	1.3	25
150	SEOM clinical guidelines in advanced and recurrent breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 31-45.	1.2	14
151	Truly personalized therapy – an end to the era of one size fits all. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 77-78.	12.5	8
152	Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 385-395.	1.1	15
153	State-of-the-art strategies for targeting the DNA damage response in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 81-104.	12.5	736
154	BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy. <i>International Journal of Cancer</i> , 2019, 144, 755-766.	2.3	54
155	Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388.	0.5	9
156	The role of DNA-demethylating agents in cancer therapy. , 2020, 205, 107416.		26

#	ARTICLE	IF	CITATIONS
157	Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. <i>Gynecologic Oncology</i> , 2020, 156, 488-497.	0.6	51
158	Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. <i>Oncologist</i> , 2020, 25, e198-e202.	1.9	11
159	Patterns of recurrence and metastasis in <i>BRCA1/BRCA2</i> -associated breast cancers. <i>Cancer</i> , 2020, 126, 271-280.	2.0	74
160	Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. <i>Annals of Palliative Medicine</i> , 2020, 9, 1296-1306.	0.5	5
161	Rate of BRCA mutation in patients tested under NCCN genetic testing criteria. <i>American Journal of Surgery</i> , 2020, 219, 145-149.	0.9	13
162	UPLC-MS/MS method for the determination of talazoparib in rat plasma and its pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 177, 112850.	1.4	5
163	Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic Variant. <i>Journal of Clinical Oncology</i> , 2020, 38, 388-394.	0.8	151
164	Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2 ⁺ Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 1-11.	1.1	20
165	Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership. <i>Breast Journal</i> , 2020, 26, 488-493.	0.4	8
166	Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 218-228.	1.0	23
167	<i>BRCA1/BRCA2</i> Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies. <i>Annals of Laboratory Medicine</i> , 2020, 40, 114-121.	1.2	67
168	Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. <i>Clinical Cancer Research</i> , 2020, 26, 657-668.	3.2	70
169	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2020, 16, 4439-4453.	1.1	29
170	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 321-328.	1.0	25
171	PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 718-729.	0.5	13
172	AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 18.	1.1	19
173	Expression of tumor-associated antigens in breast cancer subtypes. <i>Breast</i> , 2020, 49, 202-209.	0.9	24
174	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	1.1	5

#	ARTICLE	IF	CITATIONS
175	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28073.	0.8	52
176	Precision Medicine and Targeted Therapies in Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 51-62.	0.6	32
177	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. <i>Translational Oncology</i> , 2020, 13, 410-422.	1.7	52
178	Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e37-e55.	1.4	16
179	Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i> , 2020, 22, 681-685.	1.1	20
180	Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. , 2020, 207, 107450.		101
181	Esophageal carcinoma: Towards targeted therapies. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 195-209.	2.1	99
182	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 709-718.	1.1	44
183	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , 2020, 26, 1372-1384.	3.2	66
184	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. <i>Drugs</i> , 2020, 80, 131-146.	4.9	10
185	Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 121-126.	1.0	24
186	Delving into PARP inhibition from bench to bedside and back. , 2020, 206, 107446.		11
187	Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 771-778.	1.1	22
188	Talazoparib in Patients with a Germline <i>BRCA</i> -Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. <i>Oncologist</i> , 2020, 25, e439-e450.	1.9	61
189	Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 273-281.	0.8	4
190	Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020. <i>Breast Journal</i> , 2020, 26, 69-80.	0.4	31
191	An Emerging Regulatory Role for the Tumor Microenvironment in the DNA Damage Response to Double-Strand Breaks. <i>Molecular Cancer Research</i> , 2020, 18, 185-193.	1.5	28
192	PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes—Implications for UV-Induced DNA Repair and Photocarcinogenesis. <i>Cancers</i> , 2020, 12, 5.	1.7	36

#	ARTICLE	IF	CITATIONS
193	Clinical assays for assessment of homologous recombination DNA repair deficiency. <i>Gynecologic Oncology</i> , 2020, 159, 887-898.	0.6	70
194	Can we cure oligometastatic disease? A practical point of view. <i>Current Opinion in Oncology</i> , 2020, 32, 568-574.	1.1	5
195	<p>Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9375-9387.	0.9	16
196	Survival benefits of PARP inhibitors in advanced breast cancer: aÂmirage?. <i>Annals of Oncology</i> , 2020, 31, 1432-1434.	0.6	4
198	Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. <i>Life Sciences</i> , 2020, 261, 118434.	2.0	23
199	Targeting the intrinsically disordered architectural High Mobility Group A (HMGA) oncoproteins in breast cancer: learning from the past to design future strategies. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 953-969.	1.5	7
200	Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. <i>Current Opinion in Oncology</i> , 2020, 32, 585-593.	1.1	3
201	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020, 6, 54.	2.3	181
202	The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 1002-1013.	1.4	18
203	5th ESO-ESMO international consensus guidelines for advanced breastÂcancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649.	0.6	761
204	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 943-953.	1.9	19
207	Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. <i>Annals of Oncology</i> , 2020, 31, 1526-1535.	0.6	214
208	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
209	The DNA damaging revolution. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103117.	2.0	9
210	ABC4 Consensus: First Latin American Meetingâ€™ Assessment, Comments, and Application of Its Recommendations. <i>JCO Global Oncology</i> , 2020, 6, 819-827.	0.8	2
211	Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology. <i>JCO Global Oncology</i> , 2020, 6, 991-1008.	0.8	9
213	SurgicalÂand Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 553080.	1.3	14
214	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	2.2	60

#	ARTICLE	IF	CITATIONS
215	Poly(ADP-ribose)polymerase1: A potential molecular marker to identify cancer during colposcopy procedures.. Journal of Nuclear Medicine, 2020, 62, jnumed.120.253575.	2.8	3
216	Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?. ESMO Open, 2020, 5, e001112.	2.0	30
217	Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype. Cancers, 2020, 12, 3298.	1.7	15
218	Health Care Disparities and Demand for Expanding Hereditary Breast Cancer Screening Guidelines in African Americans. Clinical Breast Cancer, 2021, 21, e220-e227.	1.1	7
219	PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches. Journal of Thoracic Disease, 2020, 12, 6240-6252.	0.6	26
220	Update Breast Cancer 2020 Part 4 " Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1115-1122.	0.8	11
221	Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology. Frontiers in Oncology, 2020, 10, 611127.	1.3	0
222	Combinatorial Therapy of High Dose Vitamin C and PARP Inhibitors in DNA Repair Deficiency: A Series of 8 Patients. Integrative Cancer Therapies, 2020, 19, 153473542096981.	0.8	8
223	Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma. JAMA - Journal of the American Medical Association, 2020, 324, 1957.	3.8	33
224	Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant. Npj Breast Cancer, 2020, 6, 31.	2.3	13
225	Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast Cancer Research and Treatment, 2020, 184, 265-275.	1.1	22
227	The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy"Current progress and future direction. European Journal of Medicinal Chemistry, 2020, 203, 112570.	2.6	45
228	Homologous repair deficiency score for identifying breast cancers with defective DNA damage response. Scientific Reports, 2020, 10, 12506.	1.6	23
229	Patterns and Prevalence of Germline BRCA1 and BRCA2 Mutations among High-Risk Breast Cancer Patients in Jordan: A Study of 500 Patients. Journal of Oncology, 2020, 2020, 1-7.	0.6	10
230	Update on multi-gene panel testing and communication of genetic test results. Breast Journal, 2020, 26, 1513-1519.	0.4	9
231	Current and emerging biologic therapies for triple negative breast cancer. Expert Opinion on Biological Therapy, 2022, 22, 591-602.	1.4	11
232	Novel targeted therapies for metastatic breast cancer. Annals of Translational Medicine, 2020, 8, 907-907.	0.7	10
233	Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Research, 2020, 22, 114.	2.2	25

#	ARTICLE	IF	CITATIONS
234	Synthetic Lethality through the Lens of Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14151-14183.	2.9	31
235	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	0.8	276
237	The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1199-1208.	1.9	17
238	Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. <i>Breast Cancer</i> , 2021, 28, 1167-1180.	1.3	118
239	Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 689-698.	1.1	4
240	Poly(ADP-ribose) polymerase inhibition: past, present and future. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 711-736.	21.5	275
241	Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. <i>Journal of Hematology and Oncology</i> , 2020, 13, 118.	6.9	95
242	PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 54.	0.7	21
243	Genomic Signatures in Luminal Breast Cancer. <i>Breast Care</i> , 2020, 15, 355-365.	0.8	20
244	Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology. <i>Personalized Medicine</i> , 2020, 17, 399-420.	0.8	7
245	Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition. <i>Cancers</i> , 2020, 12, 2684.	1.7	30
247	Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor. <i>Nature Communications</i> , 2020, 11, 4875.	5.8	24
249	Critical Analysis of Genome-Wide Association Studies: Triple Negative Breast Cancer Quae Exempli Causa. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5835.	1.8	7
250	BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?. <i>Lancet Oncology, The</i> , 2020, 21, 1254-1255.	5.1	1
251	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1269-1282.	5.1	207
252	Strategies to enhance identification of hereditary breast cancer gene carriers. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 861-865.	1.5	1
253	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171
254	BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. <i>EBioMedicine</i> , 2020, 60, 102988.	2.7	27

#	ARTICLE	IF	CITATIONS
255	Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?. JCO Precision Oncology, 2020, 4, 1034-1037.	1.5	6
256	RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer. Cancers, 2020, 12, 2539.	1.7	2
257	Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling. Current Genetic Medicine Reports, 2020, 8, 109-119.	1.9	0
258	Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs, 2020, 80, 1685-1697.	4.9	72
259	Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer. Experimental Hematology and Oncology, 2020, 9, .	2.0	7
260	Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2020, 4, 1012-1024.	1.5	11
261	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Frontiers in Cell and Developmental Biology, 2020, 8, 564601.	1.8	315
262	<p>Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes</p>. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 227-238.	0.4	8
264	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. Breast Care, 2020, 15, 608-618.	0.8	8
265	Utility of Circulating Tumor DNA in Different Clinical Scenarios of Breast Cancer. Cancers, 2020, 12, 3797.	1.7	4
266	Impact of variants in ATP-binding cassetteÂtransporters on breast cancer treatment. Pharmacogenomics, 2020, 21, 1299-1310.	0.6	9
267	Molecular Features and Clinical Management of Hereditary Gynecological Cancers. International Journal of Molecular Sciences, 2020, 21, 9504.	1.8	13
268	Systemic Therapy for Estrogen Receptorâ€Positive, HER2-Negative Breast Cancer. New England Journal of Medicine, 2020, 383, 2557-2570.	13.9	146
269	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIRO2-Lung Trial. JTO Clinical and Research Reports, 2020, 1, 100068.	0.6	10
270	Breast cancer in global health: beyond diversity and inequality. International Journal of Surgery Global Health, 2020, 3, e32-e32.	0.2	4
271	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. Cancers, 2020, 12, 3256.	1.7	8
273	Management of early breast cancer in patients bearing germline BRCA mutations. Seminars in Oncology, 2020, 47, 243-248.	0.8	3
274	Clinical Trials in Metastatic Uveal Melanoma: Current Status. Ocular Oncology and Pathology, 2020, 6, 381-387.	0.5	16

#	ARTICLE	IF	CITATIONS
275	Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e2019452.	2.8	76
276	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	3.4	4
277	Drug Repurposing for Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2020, 10, 200.	1.1	29
278	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.	3.2	95
279	Implications of BRCA Germline Mutations on Breast Cancer Medical Treatment. <i>Current Breast Cancer Reports</i> , 2020, 12, 59-65.	0.5	0
280	What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70.	1.8	13
281	BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy. <i>Cancers</i> , 2020, 12, 1252.	1.7	15
282	Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. <i>International Journal of Cancer</i> , 2020, 147, 2658-2668.	2.3	13
283	Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i> , 2020, 22, 1142-1148.	1.1	59
284	Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. <i>Cancer Medicine</i> , 2020, 9, 5035-5050.	1.3	8
285	Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020, 12, 125-131.	0.5	29
286	Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 491-502.	1.1	2
287	Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations in the EMBRACA and ABRAZO Trials. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1334-1343.	1.0	12
288	Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. <i>Nature Communications</i> , 2020, 11, 2662.	5.8	157
289	Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.	5.7	23
290	Atezolizumab in the treatment of metastatic triple-negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 981-989.	1.4	20
291	Integrating Genetic and Genomic Testing Into Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e259-e263.	1.8	6
292	PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. <i>Cancers</i> , 2020, 12, 1378.	1.7	29

#	ARTICLE	IF	CITATIONS
293	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3805.	1.8	17
294	Talazoparib Exposureâ€Efficacy Analysis in Patients With Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations in the EMBRACA Trial. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1324-1333.	1.0	10
295	The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102988.	2.0	25
296	A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib. <i>Anticancer Research</i> , 2020, 40, 2509-2514.	0.5	8
297	Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 570.	1.3	127
298	Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both <i>BRCA1</i> and <i>BRCA2</i> : A Single-Center Experience. <i>Cancers</i> , 2020, 12, 1306.	1.7	0
299	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
300	Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer. <i>Pharmaceutics</i> , 2020, 12, 524.	2.0	22
301	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non- <i>BRCA1/2</i> -Mutant Cancers. <i>Cancer Discovery</i> , 2020, 10, 1528-1543.	7.7	82
302	Inhibition of CSF1R and AKT by (Â±)-kusunokinin hinders breast cancer cell proliferation. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110361.	2.5	19
303	Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	3.2	12
304	Strategic consideration for effective chemotherapeutic transportation via transpapillary route in breast cancer. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119563.	2.6	19
305	Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. <i>BMC Cancer</i> , 2020, 20, 507.	1.1	48
306	Consolidated <i>BRCA1/2</i> Variant Interpretation by MH <i>BRCA</i> Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3895.	1.8	4
307	Clinical Characteristics and Exploratory Genomic Analyses of Germline <i>BRCA1</i> or <i>BRCA2</i> Mutations in Breast Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1315-1325.	1.5	8
308	Pharmacological management of male breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1493-1504.	0.9	3
309	A Population-Based Analysis of Breast Cancer Incidence and Survival by Subtype in Ontario Women. <i>Current Oncology</i> , 2020, 27, 191-198.	0.9	20
310	Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	11

#	ARTICLE	IF	CITATIONS
311	Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features. <i>Breast Care</i> , 2020, 15, 208-216.	0.8	6
313	A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 643-654.	1.1	45
314	Panel Testing for Hereditary Breast Cancer: More or Less?. <i>Current Breast Cancer Reports</i> , 2020, 12, 45-50.	0.5	0
315	How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989753.	1.4	8
316	The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. <i>Cell and Bioscience</i> , 2020, 10, 35.	2.1	57
317	Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. <i>Oncologist</i> , 2020, 25, e900-e908.	1.9	15
318	International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus Assessment by a German Group of Experts. <i>Breast Care</i> , 2020, 15, 82-95.	0.8	25
319	Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. <i>JCO Global Oncology</i> , 2020, 6, 439-452.	0.8	25
320	Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years. <i>Breast</i> , 2020, 50, 113-124.	0.9	10
321	Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 277-287.	0.8	16
322	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , 2020, 395, 1078-1088.	6.3	302
323	Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090909.	1.4	14
324	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. <i>Drugs in R and D</i> , 2020, 20, 55-73.	1.1	84
325	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72
326	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020, 12, 819.	1.7	61
327	PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. <i>Molecular Cancer</i> , 2020, 19, 49.	7.9	145
328	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1409-1418.	0.8	64
329	Developing effective combination therapy for pancreatic cancer: An overview. <i>Pharmacological Research</i> , 2020, 155, 104740.	3.1	46

#	ARTICLE	IF	CITATIONS
330	2. Therapie des metastasierten Mammakarzinoms. , 2020, , 71-120.		0
331	4. Supportivtherapie. , 2020, , 127-216.		0
332	Optimal Systemic Treatment for Early Triple-Negative Breast Cancer. Breast Care, 2020, 15, 217-226.	0.8	19
333	Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma. Current Treatment Options in Oncology, 2020, 21, 62.	1.3	5
334	Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast cancer patients: a retrospective chart review study. Hereditary Cancer in Clinical Practice, 2020, 18, 13.	0.6	0
335	Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier. Breast Journal, 2020, 26, 1506-1512.	0.4	1
336	Homologous recombination deficiency in breast cancer. Memo - Magazine of European Medical Oncology, 2020, 13, 375-379.	0.3	2
338	Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia, 2020, 22, 431-440.	2.3	58
339	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. Cancer Treatment Reviews, 2020, 88, 102064.	3.4	41
340	The evolving management of metastatic triple negative breast cancer. Seminars in Oncology, 2020, 47, 229-237.	0.8	28
341	Early stage triple negative breast cancer: Management and future directions. Seminars in Oncology, 2020, 47, 201-208.	0.8	23
342	ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019. Geburtshilfe Und Frauenheilkunde, 2020, 80, 588-600.	0.8	1
343	Tackling the Biological Diversity in Early Triple-Negative Breast Cancer. Breast Care, 2020, 15, 205-207.	0.8	2
345	PARP and PARC inhibitors in cancer treatment. Genes and Development, 2020, 34, 360-394.	2.7	360
346	PARP inhibitors: a tsunami of indications in different malignancies. Pharmacogenomics, 2020, 21, 221-230.	0.6	16
347	BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. Diagnostics, 2020, 10, 119.	1.3	6
348	Health Disparities in Germline Genetic Testing for Cancer Susceptibility. Current Breast Cancer Reports, 2020, 12, 51-58.	0.5	6
349	A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. Nature Communications, 2020, 11, 822.	5.8	62

#	ARTICLE	IF	CITATIONS
350	Management of Male Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1849-1863.	0.8	122
351	The kinase polypharmacology landscape of clinical PARP inhibitors. <i>Scientific Reports</i> , 2020, 10, 2585.	1.6	68
352	The paradox of cancer genes in non-malignant conditions: implications for precision medicine. <i>Genome Medicine</i> , 2020, 12, 16.	3.6	33
353	Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 59-65.	0.4	13
354	The antitumorigenic roles of BRCA1 and BARD1 in DNA repair and replication. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 284-299.	16.1	199
355	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 679-686.	0.9	3
356	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz085.	1.4	24
357	Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 687-699.	0.9	41
358	Establishment and Characterization of a Brca1 ^{-/-} , p53 ^{-/-} Mouse Mammary Tumor Cell Line. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1185.	1.8	10
359	Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109661.	2.5	58
360	Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer. <i>High-Throughput</i> , 2020, 9, 1.	4.4	22
361	A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. <i>Investigational New Drugs</i> , 2020, 38, 1400-1410.	1.2	25
362	Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	30
363	Lessons Learned from Direct-to-Consumer Genetic Testing. <i>Clinics in Laboratory Medicine</i> , 2020, 40, 83-92.	0.7	4
364	Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 6230-6245.	2.0	17
365	Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, e196400.	3.4	32
366	Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00149.	1.3	8
367	Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2080-2106.	0.8	178

#	ARTICLE	IF	CITATIONS
368	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232
369	Molecular profiling in breast cancer—ready for clinical routine?. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 445-449.	0.3	7
370	ESO—ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020, 31, 674-696.	0.6	172
371	Biologic therapy for advanced breast cancer: recent advances and future directions. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1009-1024.	1.4	23
372	A novel lncRNA PLK4 up-regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP-mediated cell senescence. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 5304-5316.	1.6	14
373	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 903-915.	1.2	52
374	Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1. <i>Cells</i> , 2020, 9, 941.	1.8	3
375	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	3.2	54
376	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. <i>Chinese Medical Journal</i> , 2020, 133, 853-862.	0.9	21
377	53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 930.	1.7	7
378	Update Breast Cancer 2020 Part 2 — Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 391-398.	0.8	12
379	Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 465-473.	1.1	16
380	Molecular subtypes and precision treatment of triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 499-499.	0.7	64
381	Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. <i>Molecular Cancer Research</i> , 2020, 18, 968-980.	1.5	18
382	Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 160.	1.8	46
383	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 828.	1.7	27
384	Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. <i>Journal of Clinical Medicine</i> , 2020, 9, 940.	1.0	79
385	Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience. <i>Breast Care</i> , 2021, 16, 173-180.	0.8	3

#	ARTICLE	IF	CITATIONS
386	PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. <i>Blood Reviews</i> , 2021, 45, 100696.	2.8	17
387	Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 1-9.	1.1	11
388	Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 241-255.	0.7	10
389	Prognostic and predictive parameters in breast pathology: a pathologist's primer. <i>Modern Pathology</i> , 2021, 34, 94-106.	2.9	14
390	Parthanatos and its associated components: Promising therapeutic targets for cancer. <i>Pharmacological Research</i> , 2021, 163, 105299.	3.1	50
391	PARP inhibition in homologous-recombination-deficient early-stage breast cancer. <i>Annals of Oncology</i> , 2021, 32, 4-5.	0.6	1
392	Progress in systemic therapy for triple-negative breast cancer. <i>Frontiers of Medicine</i> , 2021, 15, 1-10.	1.5	16
393	Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. <i>Annals of Pharmacotherapy</i> , 2021, 55, 921-931.	0.9	38
394	Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 139-143.	1.2	6
395	PARP Inhibitors in Cancer Diagnosis and Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1585-1594.	3.2	53
396	Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 240-249.	0.6	115
397	PARP inhibitors coming of age. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 69-70.	12.5	18
398	Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 358-372.	1.5	18
399	Treatment strategies for breast cancer brain metastases. <i>British Journal of Cancer</i> , 2021, 124, 142-155.	2.9	117
400	Triple-negative breast cancer: promising prognostic biomarkers currently in development. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 135-148.	1.1	80
401	Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. <i>Advances in Therapy</i> , 2021, 38, 109-136.	1.3	23
402	Training courses on hereditary breast and ovarian cancer to strengthen cross-sectoral care in underserved areas. <i>Patient Education and Counseling</i> , 2021, 104, 1431-1437.	1.0	2
403	Proteomic analysis of talazoparib resistance in triple-negative breast cancer cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22678.	1.4	6

#	ARTICLE	IF	CITATIONS
404	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 66-82.	5.7	126
405	Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating In Vitro and In Vivo Encapsulated Drug Delivery. <i>Advanced Therapeutics</i> , 2021, 4, 2000125.	1.6	6
406	BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188459.	3.3	5
407	A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, 99-e217.	1.9	49
408	Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). <i>Annals of Oncology</i> , 2021, 32, 49-57.	0.6	92
409	Oligometastatic breast cancer: where are we now and where are we headed?â€”a narrative review. <i>Annals of Palliative Medicine</i> , 2020, 9, 62-62.	0.5	29
410	Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 73-84.	1.1	16
411	Systemic Therapy for the Treatment of Breast Cancer. , 2021, , 81-87.		0
412	Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study. <i>Breast Cancer</i> , 2021, 28, 672-683.	1.3	0
413	Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 109-117.	2.3	10
414	â€œTriple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinicâ€. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 76-82.	1.0	4
415	Immunotherapy in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 59-66.	1.0	36
416	BRCA testing and outcomes in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 839-850.	1.1	5
417	Isochromanoidenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation. <i>International Journal of Biological Sciences</i> , 2021, 17, 986-994.	2.6	2
418	Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. <i>Breast Care</i> , 2021, 16, 115-128.	0.8	10
419	DNA Damage Repair Inhibitor for Breast Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 159-179.	0.8	0
420	PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 67-75.	1.0	7
421	Haematologic toxicities with PARP inhibitors in cancer patients: an upâ€”toâ€”date metaâ€”analysis of 29 randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 571-584.	0.7	26

#	ARTICLE	IF	CITATIONS
423	Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 818-827.	0.5	13
424	Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in <i>Brca1</i> -deficient mice. <i>Scientific Reports</i> , 2021, 11, 1234.	1.6	5
425	BRCA Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients. <i>International Journal of Pharmaceutical Research and Allied Sciences</i> , 2021, 10, 33-49.	0.1	1
426	The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2111-2119.	0.7	45
427	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab007.	1.4	11
428	The advance of adjuvant treatment for triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	11
429	Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 589-607.	1.0	29
430	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 108-114.	0.8	3
431	Clinical application of liquid biopsies to detect somatic <i>BRCA1/2</i> mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. <i>Oncotarget</i> , 2021, 12, 63-65.	0.8	1
432	Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 101-107.	0.8	2
433	A novel germline <i>BRCA1</i> mutation identified in a family with hereditary breast and ovarian cancer syndrome. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110285.	0.6	2
434	Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 636.	1.8	29
435	Hereditary Cancer Counseling and Germline Genetic Testing. , 2021, , 305-317.		0
436	Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. <i>Lancet Haematology</i> , 2021, 8, e122-e134.	2.2	139
437	From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care. <i>JCO Precision Oncology</i> , 2021, 5, 403-407.	1.5	3
438	Atezolizumab and <i>nab</i> -Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the <i>IMpassion130</i> Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	3.0	171
439	Awareness and Availability of Routine Germline <i>BRCA1/2</i> Mutation Testing in Patients with Advanced Breast Cancer in Germany. <i>Breast Care</i> , 2022, 17, 40-46.	0.8	3
440	Local Laboratory Testing of Germline <i>BRCA</i> Mutations vs. Myriad: A Single-Institution Experience in Korea. <i>Diagnostics</i> , 2021, 11, 370.	1.3	2

#	ARTICLE	IF	CITATIONS
441	Amongst Women Stratified to Receive Endocrine Therapy on the Basis of Their Tumor Estrogen and Progesterone Receptor Levels, Those with Higher Tumor Progesterone Receptor Levels Had a Better Outcome Than Those with Lower Levels of Tumor Progesterone Receptor. <i>Cancers</i> , 2021, 13, 905.	1.7	4
442	Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. <i>Journal of International Medical Research</i> , 2021, 49, 030006052199101.	0.4	5
444	Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2021, 33, 452-461.	0.7	5
445	Therapeutic Advances in Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2008.	1.8	22
447	A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. <i>International Journal of Cancer</i> , 2021, 148, 3041-3050.	2.3	5
448	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1725-1741.	2.8	53
449	Clinicopathological Characteristics and Treatment Strategies of Triple-Negative Breast Cancer Patients With a Survival Longer than 5 Years. <i>Frontiers in Oncology</i> , 2020, 10, 617593.	1.3	5
450	Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). <i>ESMO Open</i> , 2021, 6, 100019.	2.0	12
451	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 894.	1.7	6
452	Clinical application of circulating tumor DNA in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1431-1442.	1.2	5
454	Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. <i>Cancers</i> , 2021, 13, 1586.	1.7	9
455	Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 1080.	1.7	10
456	Overview of recent advances in metastatic triple negative breast cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 164-182.	0.9	42
457	American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline for Management of Hereditary Breast Cancer. <i>JAMA Surgery</i> , 2021, 156, 284.	2.2	8
458	Cisplatin +/rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 29.	2.3	15
459	Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles Heel. <i>Cancers</i> , 2021, 13, 1392.	1.7	29
460	A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. <i>Oral Oncology</i> , 2021, 114, 105171.	0.8	13
461	Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3201-3214.	3.2	27

#	ARTICLE	IF	CITATIONS
462	Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 451-461.	1.9	6
463	Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?. <i>Journal of Personalized Medicine</i> , 2021, 11, 245.	1.1	14
464	PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. <i>Aging</i> , 2021, 13, 8975-8988.	1.4	13
465	The overexpression of DNA repair genes in invasive ductal and lobular breast carcinomas: Insights on individual variations and precision medicine. <i>PLoS ONE</i> , 2021, 16, e0247837.	1.1	6
466	The PARP Way to Epigenetic Changes. <i>Genes</i> , 2021, 12, 446.	1.0	24
467	Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. <i>Cancer Research and Treatment</i> , 2021, 53, 1084-1095.	1.3	5
468	Modeling and targeting of erythroleukemia by hematopoietic genome editing. <i>Blood</i> , 2021, 137, 1628-1640.	0.6	25
469	The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors. <i>Clinical Pharmacokinetics</i> , 2021, 60, 921-930.	1.6	6
470	An Overview of PARP Inhibitors for the Treatment of Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 255-282.	1.7	182
471	Hereditary breast cancer and ovarian cancer: clinical course and treatment. <i>Opuholi Zenskoj Reproktivnoy Sistemy</i> , 2021, 16, 54-65.	0.1	0
472	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3243-3252.	3.2	14
473	Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 57.	1.8	30
474	Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. <i>British Journal of Cancer</i> , 2021, 125, 7-14.	2.9	14
475	Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives. <i>Cancers</i> , 2021, 13, 1078.	1.7	41
476	Prostate cancer and PARP inhibitors: progress and challenges. <i>Journal of Hematology and Oncology</i> , 2021, 14, 51.	6.9	68
477	Clinical cancer genomic profiling. <i>Nature Reviews Genetics</i> , 2021, 22, 483-501.	7.7	79
478	A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies. <i>Current Medicinal Chemistry</i> , 2021, 28, 1565-1584.	1.2	5
479	Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females. <i>Journal of Community Genetics</i> , 2021, 12, 431-438.	0.5	3

#	ARTICLE	IF	CITATIONS
481	Personalized and targeted therapies. <i>ChemistrySelect</i> , 2023, 8, 2103-2126.	0.7	0
482	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 676-686.	1.5	20
483	DNA damage response inhibitors: An avenue for TNBC treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188521.	3.3	26
484	PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer. <i>Medical Oncology</i> , 2021, 38, 61.	1.2	2
485	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021, 6, 100040.	2.0	19
486	Zebrafish Avatar to Develop Precision Breast Cancer Therapies.. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, .	0.9	3
487	Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil. <i>Surgical and Experimental Pathology</i> , 2021, 4, .	0.2	2
488	Cyclin-dependent kinase 4 and 6 inhibitors at the crossroads: the combinational therapeutic strategies in breast cancer—a narrative review. <i>Translational Breast Cancer Research</i> , 2021, 2, 13-13.	0.4	0
489	Prognostic factors for patients with metastatic breast cancer: a literature review. <i>Translational Cancer Research</i> , 2021, 10, 1644-1655.	0.4	0
490	Genomic Correlates of DNA Damage in Breast Cancer Subtypes. <i>Cancers</i> , 2021, 13, 2117.	1.7	3
491	Molecular Prognostic and Predictive Markers in Triple - Negative Breast Cancer. , 0, , .		2
492	PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. <i>The Cochrane Library</i> , 2021, 2021, CD011395.	1.5	19
493	Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. <i>Cancers</i> , 2021, 13, 1656.	1.7	16
494	Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 131-147.	1.0	5
495	Synthetic Lethality in Cancer Therapeutics: The Next Generation. <i>Cancer Discovery</i> , 2021, 11, 1626-1635.	7.7	91
497	Precision medicine for the treatment of triple negative breast cancer: opportunities and challenges. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 259-270.	0.4	1
498	The emerging role of RNA N6-methyladenosine methylation in breast cancer. <i>Biomarker Research</i> , 2021, 9, 39.	2.8	22
499	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	5.8	116

#	ARTICLE	IF	CITATIONS
500	Glycans unique to the relapse-prone subset within triple-negative breast cancer as revealed by lectin array-based analysis of surgical specimens. <i>PLoS ONE</i> , 2021, 16, e0250747.	1.1	5
501	Triple-negative breast cancer: A run-through of features, classification and current therapies (Review). <i>Oncology Letters</i> , 2021, 22, 512.	0.8	52
503	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. <i>Journal of Clinical Oncology</i> , 2021, 39, 1631-1640.	0.8	62
504	Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1803-1822.	0.9	24
505	Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive. <i>Pharmaceuticals</i> , 2021, 14, 455.	1.7	18
506	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2262.	1.7	9
507	Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier. <i>Journal of the Formosan Medical Association</i> , 2021, , .	0.8	2
508	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer – Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	0.8	39
509	Breast cancer. <i>Lancet</i> , The, 2021, 397, 1750-1769.	6.3	731
510	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (â€œMETRICâ€): a randomized multicenter study. <i>Npj Breast Cancer</i> , 2021, 7, 57.	2.3	26
511	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 48.	2.3	3
513	Present and Future for PARP Inhibitors in Ovarian Cancer. <i>Advances in Oncology</i> , 2021, 1, 139-154.	0.1	0
514	<i>BRCA</i> mutated pancreatic cancer: A change is coming. <i>World Journal of Gastroenterology</i> , 2021, 27, 1943-1958.	1.4	42
515	Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2929-2939.	1.0	3
516	Update Breast Cancer 2021 Part 1 – Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 526-538.	0.8	10
517	Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment. <i>Cancers</i> , 2021, 13, 2559.	1.7	21
518	Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 216-226.	0.5	5
519	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2128-2137.	0.8	7

#	ARTICLE	IF	CITATIONS
520	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. <i>Clinical Lung Cancer</i> , 2021, 22, 187-194.e1.	1.1	18
521	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	1.3	41
522	Genetic variations in 3'UTRs of <i>SMUG1</i> and <i>NEIL2</i> genes modulate breast cancer risk, survival and therapy response. <i>Mutagenesis</i> , 2021, 36, 269-279.	1.0	5
523	PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data. <i>Oral Oncology</i> , 2021, 117, 105292.	0.8	21
524	Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-23.	0.9	3
525	FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration. <i>Frontiers in Oncology</i> , 2021, 11, 653005.	1.3	6
526	Clinical Trials and Breast Cancer Disparities. <i>Current Breast Cancer Reports</i> , 2021, 13, 186-196.	0.5	3
527	Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	13.9	764
528	Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. <i>Gynecologic Oncology</i> , 2021, 161, 653-659.	0.6	26
529	PARP inhibitor treatment of advanced breast cancer beyond the <i>BRCA</i> -mutated type: a meta-analysis. <i>Future Oncology</i> , 2021, 17, 2381-2393.	1.1	7
530	Patterns and Prevalence of <i>BRCA1</i> and <i>BRCA2</i> Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives. <i>Cancer Management and Research</i> , 2021, Volume 13, 4597-4604.	0.9	4
531	An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers. <i>Cancers</i> , 2021, 13, 3113.	1.7	0
532	A Case-Based Approach to Understanding Complex Genetic Information in an Evolving Landscape. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e328-e338.	1.8	2
533	Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. <i>Frontiers in Oncology</i> , 2021, 11, 686776.	1.3	13
534	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 537-547.	2.7	58
535	Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study. <i>Investigational New Drugs</i> , 2021, 39, 1568-1576.	1.2	5
536	Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition. <i>Scientific Reports</i> , 2021, 11, 11757.	1.6	14
537	Trials of Immunotherapy in Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 171-185.	0.5	1

#	ARTICLE	IF	CITATIONS
538	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
539	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. <i>Oncologist</i> , 2021, 26, 835-844.	1.9	16
540	Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 605-611.	1.1	4
541	Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. <i>Breast</i> , 2021, 57, 86-94.	0.9	6
542	Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!. <i>Oncology Reviews</i> , 2021, 15, 544.	0.8	4
543	Update Breast Cancer 2021 Part 3 â€“ Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 654-665.	0.8	4
544	A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors. <i>Nature Cancer</i> , 2021, 2, 598-610.	5.7	168
545	NGS in Lung, Breast, and Unknown Primary Cancer in Colombia: A Multidisciplinary Consensus on Challenges and Opportunities. <i>JCO Global Oncology</i> , 2021, 7, 1012-1023.	0.8	7
546	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. <i>SLAS Discovery</i> , 2021, 26, 1107-1124.	1.4	30
547	Triple negative breast cancer: emerging light on the horizonâ€”a narrative review. <i>Precision Cancer Medicine</i> , 0, 4, 12-12.	1.8	1
548	Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 681476.	1.3	71
549	Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). <i>Clinical Cancer Research</i> , 2021, 27, 4983-4993.	3.2	9
550	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. <i>Oncologist</i> , 2021, 26, 827-834.	1.9	28
551	A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 1-9.	1.1	6
552	Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan. <i>Scientific Reports</i> , 2021, 11, 14906.	1.6	5
553	Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer. <i>Molecular Oncology</i> , 2022, 16, 2413-2431.	2.1	3
554	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
555	Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. <i>World Journal of Clinical Oncology</i> , 2021, 12, 544-556.	0.9	7

#	ARTICLE	IF	CITATIONS
556	Are there monogenic hereditary forms of bladder cancer or only genetic susceptibilities?. <i>Pharmacogenomics</i> , 2021, 22, 619-628.	0.6	2
557	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 773-791.	12.5	198
558	Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1825-1837.	0.9	11
559	The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 871-878.	2.3	10
560	A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status. <i>Oncology and Therapy</i> , 2021, 9, 575-589.	1.0	26
561	Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258.	0.8	4
562	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7154.	1.8	5
563	Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. <i>Clinical Cancer Research</i> , 2021, 27, 5482-5491.	3.2	25
564	Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7884.	1.8	8
565	Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2 ⁻ negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 1-13.	1.1	3
566	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021, 152, 68-77.	1.3	18
567	Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223.	3.4	34
568	Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3959-3977.	0.8	121
569	TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. <i>Biomedicines</i> , 2021, 9, 876.	1.4	41
570	Genetic Landscape of Male Breast Cancer. <i>Cancers</i> , 2021, 13, 3535.	1.7	22
571	Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain. <i>Breast</i> , 2021, 58, 27-33.	0.9	7
572	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 975-983.	1.9	7
573	Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics. <i>JCO Precision Oncology</i> , 2021, 5, 1297-1311.	1.5	9

#	ARTICLE	IF	CITATIONS
574	Molecular pathogenesis of hereditary lung cancer: a literature review. <i>Pharmacogenomics</i> , 2021, 22, 791-803.	0.6	2
575	Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 245-253.	3.0	5
576	The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data. <i>Clinical Breast Cancer</i> , 2022, 22, 10-25.	1.1	7
577	Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention. <i>JCO Precision Oncology</i> , 2021, 5, 1387-1396.	1.5	23
578	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	0.9	1
579	Novel RAF/MEK inhibitor CH5126766/VS6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer. <i>Cancer Science</i> , 2021, 112, 4166-4175.	1.7	6
580	Breast Cancer Treatments: Updates and New Challenges. <i>Journal of Personalized Medicine</i> , 2021, 11, 808.	1.1	108
581	Cytotoxic and targeted therapy for BRCA1/2-driven cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 36.	0.6	11
582	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , 2021, 41, 757-773.	1.1	1
584	Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 641-651.	1.1	16
585	First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <i>Annals of Oncology</i> , 2021, 32, 983-993.	0.6	205
586	An update of new small-molecule anticancer drugs approved from 2015 to 2020. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113473.	2.6	27
587	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i> , <i>BRCA2</i> , or <i>PALB2</i> . <i>Journal of Clinical Oncology</i> , 2021, 39, 2497-2505.	0.8	113
588	Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials. <i>Annals of Translational Medicine</i> , 2021, 9, 1229-1229.	0.7	10
589	Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 8924.	1.8	1
590	Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 711402.	1.3	14
591	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	0.8	83
592	The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e16919.	0.2	2

#	ARTICLE	IF	CITATIONS
593	Targeted Therapies for Breast Cancer Brain Metastases. <i>Clinical Breast Cancer</i> , 2021, 21, 263-270.	1.1	3
594	CX-5461 Sensitizes DNA Damage Repair-Proficient Castrate-Resistant Prostate Cancer to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2140-2150.	1.9	9
595	Open questions and controversies in the systemic treatment of breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 591-596.	1.1	1
596	Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4059.	1.7	8
597	Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer. <i>Cancers</i> , 2021, 13, 4132.	1.7	4
598	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2028-2036.e2.	0.3	17
599	Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test. <i>Journal of Clinical Oncology</i> , 2021, 39, 3415-3418.	0.8	9
600	Metastatic disease to the liver: Locoregional therapy strategies and outcomes. <i>World Journal of Clinical Oncology</i> , 2021, 12, 725-745.	0.9	9
601	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1250-1264.	5.1	159
602	Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1021-1030.	0.6	4
603	Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single-Center Retrospective Study. <i>Oncologist</i> , 2021, 26, e1951-e1961.	1.9	9
604	Genetic testing in patients with triple-negative or hereditary breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 584-590.	1.1	1
605	Trends in Diagnosis and Treatment of Metastatic Cancer in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 572-579.	0.6	15
607	Landscape Analysis of Breast Cancer and Acute Myeloid Leukemia Trials Using the My Cancer Genome Clinical Trial Data Model. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 975-984.	1.0	1
608	Prevention and treatment of the side effects of poly-ADP-ribose polymerase-1 inhibitors (iPARP) in breast and ovarian cancer. <i>Revue D'Homeopathie</i> , 2021, 12, e36-e42.	0.1	0
609	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. <i>Expert Opinion on Drug Safety</i> , 2021, , 1-13.	1.0	0
610	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. <i>Clinical Cancer Research</i> , 2021, 27, 6106-6114.	3.2	9
611	A narrative review of biomarkers in advanced triple negative breast cancer. <i>Precision Cancer Medicine</i> , 0, 4, 24-24.	1.8	1

#	ARTICLE	IF	CITATIONS
612	Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer. <i>Healthcare (Switzerland)</i> , 2021, 9, 1203.	1.0	3
613	Management of hormone receptorâ€‘positive, human epidermal growth factor 2â€‘negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 189-201.	1.1	10
614	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. <i>Cancer Treatment Reviews</i> , 2021, 99, 102255.	3.4	25
615	Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 703802.	1.3	10
616	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. <i>International Immunopharmacology</i> , 2021, 98, 107876.	1.7	15
617	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 701-741.	1.7	7
618	Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. <i>Clinical Breast Cancer</i> , 2021, 21, 509-520.	1.1	13
619	A review of immune checkpoint blockade in breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 208-225.	0.8	11
620	Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. <i>ESMO Open</i> , 2021, 6, 100238.	2.0	12
621	Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer. , 2021, 9, e003468.		17
622	Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 59, 44-50.	0.9	3
623	Progress and challenges of immunotherapy in triple-negative breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188593.	3.3	106
624	Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100097.	0.1	1
625	Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review. <i>Breast</i> , 2021, 60, 26-34.	0.9	9
626	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
627	Triple Negative Breast Cancer. , 2022, , 35-48.		1
629	From <i>BRCA1</i> to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes. <i>Breast Care</i> , 2021, 16, 202-213.	0.8	7
630	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 228-235.	0.8	20

#	ARTICLE	IF	CITATIONS
631	The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature. <i>Journal of Medicine and Life</i> , 2021, 14, 17-20.	0.4	7
632	The role of PARP inhibitors in <i>BRCA</i> mutated pancreatic cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110148.	1.4	21
633	DNA Damage Response. , 2021, , 1-12.		0
634	Integrating PARP inhibitors into the management of breast cancer: where are we?. <i>Chinese Clinical Oncology</i> , 2021, 10, 50-50.	0.4	4
635	Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model. <i>International Journal of Biological Sciences</i> , 2021, 17, 689-701.	2.6	2
636	Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342110024.	0.6	16
637	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342199585.	0.6	22
638	The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492199628.	0.6	33
639	Diagnosis and Treatment of Breast Cancer in the Precision Medicine Era. <i>Methods in Molecular Biology</i> , 2020, 2204, 53-61.	0.4	23
640	Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 383-390.	1.1	18
641	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102973.	2.0	31
642	Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 56-61.	0.9	12
643	Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations. <i>Human Pathology</i> , 2020, 102, 94-103.	1.1	16
644	Atezolizumab for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 151-158.	1.1	60
645	The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 894-904.	0.6	95
646	Innovations in targeted therapies for triple negative breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 34-47.	0.9	4
651	Repositioning PARP inhibitors for SARSâ€CoVâ€2 infection(COVIDâ€19); a new multiâ€pronged therapy for acute respiratory distress syndrome?. <i>British Journal of Pharmacology</i> , 2020, 177, 3635-3645.	2.7	52
652	Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 89-93.	1.2	30

#	ARTICLE	IF	CITATIONS
653	XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097420.	1.4	10
654	Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2019, 23, 434-438.	0.3	3
655	Genomic Alteration in Metastatic Breast Cancer and Its Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 30-43.	1.8	107
656	Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series. <i>American Journal of Case Reports</i> , 2020, 21, e927008.	0.3	5
657	Triple-negative breast cancer: recent treatment advances. <i>F1000Research</i> , 2019, 8, 1342.	0.8	152
658	Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance. <i>Yeungnam University Journal of Medicine</i> , 2020, 37, 230-235.	0.7	9
659	Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. <i>PLoS ONE</i> , 2020, 15, e0239197.	1.1	13
660	A review of current progress in triple-negative breast cancer therapy. <i>Open Medicine (Poland)</i> , 2020, 15, 1143-1149.	0.6	46
661	Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis. <i>Aging</i> , 2021, 13, 450-459.	1.4	14
662	Differential gene expression and AKT targeting in triple negative breast cancer. <i>Oncotarget</i> , 2019, 10, 4356-4368.	0.8	14
663	PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. , 2019, 2, 665-679.		20
664	Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology. , 2019, 2, 608-617.		3
665	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1603-1603.	0.7	8
666	Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?. <i>Annals of Translational Medicine</i> , 2020, 8, 1706-1706.	0.7	17
667	Biliary tract cancer prognostic and predictive genomics. <i>Chinese Clinical Oncology</i> , 2019, 8, 42-42.	0.4	15
668	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 370-382.	0.7	18
669	Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. <i>Current Drug Targets</i> , 2020, 21, 167-178.	1.0	10
670	Olaparib for advanced breast cancer. <i>Future Oncology</i> , 2020, 16, 717-732.	1.1	8

#	ARTICLE	IF	CITATIONS
671	The potential of translational research in dogs in human medicine. <i>Translational and Regulatory Sciences</i> , 2019, 1, 31-36.	0.2	3
672	PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. <i>Cancers</i> , 2020, 12, 394.	1.7	91
673	Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1290.	1.8	10
674	Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 74.	1.8	15
675	Triple-negative breast cancer therapy: Current and future perspectives (Review). <i>International Journal of Oncology</i> , 2020, 57, 1245-1261.	1.4	196
676	Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 265-275.	0.4	15
677	Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, .	0.2	18
678	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 452-478.	2.3	848
679	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 380-391.	2.3	314
680	A Web-Based Tool to Automate Portions of Pretest Genetic Counseling for Inherited Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 841-847.	2.3	18
681	Identification of a novel pathogenic variant in <i>PALB2</i> and <i>BARD1</i> genes by a multigene sequencing panel in triple negative breast cancer in Morocco. <i>Journal of Genomics</i> , 2021, 9, 43-54.	0.6	4
682	Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 1008.	1.7	9
683	IMProving care After inherited Cancer Testing (IMPACT) study: protocol of a randomized trial evaluating the efficacy of two interventions designed to improve cancer risk management and family communication of genetic test results. <i>BMC Cancer</i> , 2021, 21, 1099.	1.1	5
684	Antibody drug conjugates for patients with breast cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100795.	1.0	3
685	RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain. <i>Breast</i> , 2021, 60, 302.	0.9	1
686	SABR in oligometastatic breast cancer: Current status and future directions. <i>Breast</i> , 2021, 60, 223-229.	0.9	6
687	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 246-253.	0.6	62
688	Penetrance of male breast cancer susceptibility genes: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 31-38.	1.1	10

#	ARTICLE	IF	CITATIONS
689	Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 61-81.	0.7	5
690	Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1303-1311.	1.1	8
691	Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 109-126.	0.6	9
692	Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue – A pilot study. <i>Experimental and Molecular Pathology</i> , 2021, 123, 104705.	0.9	1
693	Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 302-309.	2.9	18
694	PARP inhibitors: clinical relevance and the role of multidisciplinary cancer teams on drug safety. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 541-551.	1.0	2
695	Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. <i>Cancers</i> , 2021, 13, 5198.	1.7	10
696	Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists. <i>Journal of Clinical Oncology</i> , 2021, 39, 4020-4028.	0.8	20
697	Acknowledging Disparities in Hereditary Cancer Testing. <i>Journal of Clinical Oncology</i> , 2021, 39, 4001-4003.	0.8	2
698	De novo metastatic breast cancer arising in young women: review of the current evidence. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	6
699	Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 137-145.	1.1	0
700	Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. <i>European Journal of Medical Genetics</i> , 2021, 64, 104350.	0.7	22
702	Clinical Advances in the Treatment of Metastatic Triple Negative Breast Cancer. <i>Advances in Clinical Medicine</i> , 2019, 09, 871-876.	0.0	0
704	Current topics in hereditary breast and ovarian cancer. <i>Okayama Igakkai Zasshi</i> , 2019, 131, 89-96.	0.0	1
705	Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case. <i>Meditsinskiy Sovet</i> , 2019, , 69-72.	0.1	0
707	Hormone Receptor-Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 275-279.	0.2	0
708	PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use. <i>Opuholi Zenskoj Reproktivnoy Sistemy</i> , 2020, 16, 55-64.	0.1	0
709	Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3890-3896.	0.8	0

#	ARTICLE	IF	CITATIONS
710	Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 742139.	1.3	8
711	PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later. <i>Annals of Oncology</i> , 2021, 32, 1460-1462.	0.6	4
712	U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review. <i>Clinical Cancer Research</i> , 2022, 28, 1072-1086.	3.2	31
713	BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 718871.	1.3	6
714	Adverse events of targeted therapies approved for women's cancers. <i>International Journal of Women's Dermatology</i> , 2021, 7, 552-559.	1.1	0
715	Hereditary breast cancer: review and current approach. <i>Mastology</i> , 0, 30, .	0.1	0
716	Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14. <i>Future Medicinal Chemistry</i> , 2020, 12, 2179-2190.	1.1	1
717	Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer. <i>Meditinskiy Sovet</i> , 2020, , 143-146.	0.1	1
718	Chapter 17: Oncology: Somatic Disease and Pharmacogenomics. , 2020, , .		0
719	Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer. <i>Journal of Pharmacy and Nutrition Sciences (discontinued)</i> , 2020, 10, 46-59.	0.2	0
720	Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer. <i>Oncology & Hematology Review</i> , 2020, 16, 23.	0.2	0
721	Management of Advanced Breast Cancer in Young Women: Whatâ€™s New in Systemic Treatment. , 2020, , 127-142.		0
722	State of the Art for Metastatic Histologies. , 2020, , 211-233.		0
723	Precision Oncology. <i>RSC Detection Science</i> , 2020, , 345-362.	0.0	1
725	Current and Future Directions for PARP Inhibition. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 297-300.	0.2	0
726	2018â€™2019 Drug Updates in Solid Tumors. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 255-258.	0.2	0
727	Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 266-270.	0.2	0
728	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021, 32, 1475-1495.	0.6	454

#	ARTICLE	IF	CITATIONS
729	Practice-Changing Interventions in the Systemic Management of Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 941-944.	2.3	0
730	Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer. Journal of Pharmacy and Nutrition Sciences (discontinued), 2020, 10, 155-168.	0.2	0
731	Post-neoadjuvant treatment of breast cancer. Meditsinskiy Sovet, 2020, , 232-241.	0.1	0
732	Personomics – an innovative tool of precision medicine and its role in the individualized treatment of patients with breast cancer. Asia-Pacific Journal of Oncology, 2020, , 1-8.	0.2	0
733	PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice. Meditsinskiy Sovet, 2020, , 57-61.	0.1	0
734	Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series. Oncotarget, 2020, 11, 3279-3285.	0.8	2
736	Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a 1/2 Mutation. Journal of the Advanced Practitioner in Oncology, 2019, 10, 167-174.	0.2	26
737	Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. American Journal of Cancer Research, 2020, 10, 648-661.	1.4	15
738	BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K. American Journal of Cancer Research, 2020, 10, 1900-1918.	1.4	2
739	Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. Annals of Translational Medicine, 2020, 8, 1389.	0.7	0
740	TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models. American Journal of Cancer Research, 2021, 11, 1632-1645.	1.4	1
741	Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. Breast Care, 2021, 16, 389-395.	0.8	0
742	PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. Advances in Genetics, 2021, 108, 35-80.	0.8	5
743	Mammakarzinom. , 2022, , 340-351.		0
744	Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. Frontiers in Oncology, 2021, 11, 769280.	1.3	45
745	BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review. Oncology Research and Treatment, 2022, 45, 54-61.	0.8	6
746	Endocrine Treatment for Breast Cancer Patients Revisited – History, Standard of Care, and Possibilities of Improvement. Cancers, 2021, 13, 5643.	1.7	16
748	Treatment landscape of triple-negative breast cancer – expanded options, evolving needs. Nature Reviews Clinical Oncology, 2022, 19, 91-113.	12.5	414

#	ARTICLE	IF	CITATIONS
749	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. <i>MedComm</i> , 2021, 2, 514-530.	3.1	12
750	Advances in the management of breast cancer brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, v63-v74.	0.4	10
751	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. <i>Cancers</i> , 2021, 13, 5847.	1.7	16
752	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1777-1787.	1.5	5
754	Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study. <i>Annals of Translational Medicine</i> , 2021, 9, 1661-1661.	0.7	11
755	Young Women with Breast Cancer in Resource-Limited Settings: What We Know and What We Need to Do Better. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 641-650.	1.0	4
756	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. <i>European Journal of Cancer</i> , 2021, 159, 283-295.	1.3	24
758	PARPi: Efficacy in Hereditary Breast Cancer. , 2021, , 293-312.		0
759	DNA Damage Response. , 2021, , 536-547.		0
763	Germline Findings from Genetic Testing for Breast Cancer. , 2021, , 227-241.		0
764	Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline <i>BRCA1/2</i> mutations and hormone receptor status from the phase-3 BROCADE3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110596.	1.4	9
765	Targeting brain metastases in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 103, 102324.	3.4	46
766	Mammakarzinom: Update 2019. , 0, , .		0
768	Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. <i>Annals of Translational Medicine</i> , 2020, 8, 1389-1389.	0.7	3
769	Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. <i>Breast Care</i> , 2021, 16, 389-395.	0.8	3
770	Management of triple-negative breast cancer in the era of novel therapies: A narrative review. <i>Cancer Research Statistics and Treatment</i> , 2021, 4, 668.	0.1	4
771	Updates in HER2-Positive and Triple-Negative Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 605-609.	2.3	2
772	PARP Inhibitors in Pancreatic Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 465-475.	1.0	18

#	ARTICLE	IF	CITATIONS
773	New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 441-456.	1.0	3
774	Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <i>BRCA1/2</i> -Mutated Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1383-1390.	3.2	12
775	Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. <i>Annals of Oncology</i> , 2022, 33, 426-433.	0.6	18
776	Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1665.	1.8	48
777	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. <i>Cancers</i> , 2022, 14, 599.	1.7	8
778	Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. <i>Cancers</i> , 2022, 14, 230.	1.7	13
780	Hormonal and Targeted Treatments in Breast Cancer. , 2022, , 443-463.		3
781	A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 599-610.	1.1	4
782	Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	4
783	Roles of Protein Disulfide Isomerase in Breast Cancer. <i>Cancers</i> , 2022, 14, 745.	1.7	13
784	An overview of genetic services delivery for hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 491-500.	1.1	12
785	<i>PARP</i> mediated <i>DNA</i> damage response, genomic stability and immune responses. <i>International Journal of Cancer</i> , 2022, 150, 1745-1759.	2.3	18
786	Updates on breast biomarkers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 163-176.	1.4	33
787	Perspectives on the role of breast cancer susceptibility gene in breast cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 495-511.	1.0	1
788	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. <i>Nature Communications</i> , 2022, 13, 514.	5.8	38
789	Real-world multi-country study of <i>BRCA1/2</i> mutation testing among adult women with HER2-negative advanced breast cancer. <i>Future Oncology</i> , 2022, 18, 1089-1101.	1.1	3
790	Systemic therapy for triple-negative breast cancer: A changing landscape. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103608.	2.0	0
791	Eligibility Criteria Can Be Deceiving: How Direct and Indirect Exclusion Criteria Affects Recruitment of Under-Served Groups in Breast Cancer Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
792	The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 60.	2.4	35
793	Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 1313-1322.	3.2	16
794	Novel Insights From the Germline Landscape of Breast Cancer in Brazil. <i>Frontiers in Oncology</i> , 2021, 11, 743231.	1.3	1
795	Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience. <i>Journal of Personalized Medicine</i> , 2022, 12, 195.	1.1	1
797	Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 1033-1046.	1.2	5
798	Protective Effect of Minocycline Hydrochloride on the Mouse Embryonic Development Against Suboptimal Environment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 799042.	1.8	1
799	Advances in cGAS-STING Signaling Pathway and Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 800393.	1.8	7
800	Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours. <i>EMBO Molecular Medicine</i> , 2022, 14, e14501.	3.3	13
801	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. <i>Cancer Treatment Reviews</i> , 2022, 104, 102337.	3.4	6
802	Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. , 2022, 236, 108108.		25
803	"It was an important part of my treatment" a qualitative study of Norwegian breast Cancer patients'™ experiences with mainstreamed genetic testing. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, 6.	0.6	3
804	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	3.2	22
806	The role of PARP inhibitors in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103621.	2.0	7
807	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103539.	2.0	11
808	Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for BRCA-mutated breast cancer: A systematic review and meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1672.	0.3	0
809	Emerging treatment strategies for metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210869.	1.4	15
810	Psychosocial outcome and health behaviour intent of breast cancer patients with BRCA1/2 and PALB2 pathogenic variants unselected by a priori risk. <i>PLoS ONE</i> , 2022, 17, e0263675.	1.1	0
811	New insights into the discovery of drugs for triple-negative breast cancer metastasis. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 365-376.	2.5	3

#	ARTICLE	IF	CITATIONS
812	Breast cancer management in 2021: A primer for the obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 82, 30-45.	1.4	18
813	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 185-199.	1.5	16
814	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.	1.7	69
815	Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 845950.	1.8	4
816	Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy. <i>Cancers</i> , 2022, 14, 965.	1.7	2
817	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 1003.	1.7	18
818	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. <i>Cancers</i> , 2022, 14, 953.	1.7	16
819	Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives. <i>Cancers</i> , 2022, 14, 1152.	1.7	10
820	Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses. <i>Cancers</i> , 2022, 14, 997.	1.7	2
821	Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells. <i>Frontiers in Oncology</i> , 2022, 12, 819714.	1.3	2
822	Molecular profiling leading to personalized treatment in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	1
823	Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 837293.	2.2	23
824	Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3238.	1.8	14
825	PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients's™ CTCs. <i>Cancers</i> , 2022, 14, 1731.	1.7	7
826	Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database. <i>Hereditas</i> , 2022, 159, 18.	0.5	4
827	Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 43.	2.3	1
828	Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes. <i>JCO Precision Oncology</i> , 2022, 6, e2100140.	1.5	14
829	Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries. <i>Breast Care</i> , 2022, 17, 460-469.	0.8	3

#	ARTICLE	IF	CITATIONS
830	Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3392-3403.	1.1	7
832	Underserved groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials. <i>Journal of Clinical Epidemiology</i> , 2022, 147, 132-141.	2.4	5
833	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 593-605.	1.9	31
835	DNA repair defects in cancer and therapeutic opportunities. <i>Genes and Development</i> , 2022, 36, 278-293.	2.7	45
836	Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives. <i>Future Oncology</i> , 2022, 18, 1927-1941.	1.1	3
837	High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 49-63.	1.1	8
838	PARP Inhibitors Resistance: Mechanisms and Perspectives. <i>Cancers</i> , 2022, 14, 1420.	1.7	22
839	Circular RNAs as Potential Biomarkers in Breast Cancer. <i>Biomedicines</i> , 2022, 10, 725.	1.4	26
840	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. <i>ESMO Open</i> , 2022, 7, 100409.	2.0	25
841	PARP inhibition in breast cancer: progress made and future hopes. <i>Npj Breast Cancer</i> , 2022, 8, 47.	2.3	42
842	Identification and Management of Pathogenic Variants in <i>BRCA1</i> , <i>BRCA2</i> , and <i>PALB2</i> in a Tumor-Only Genomic Testing Program. <i>Clinical Cancer Research</i> , 2022, 28, 2349-2360.	3.2	8
843	Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?. <i>Cancers</i> , 2022, 14, 1856.	1.7	12
844	Incidence and impact of brain metastasis in patients with hereditary <i>BRCA1</i> or <i>BRCA2</i> mutated invasive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 46.	2.3	10
845	A phase I study of talazoparib (NCT02673673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCT01978222). <i>Cancer Medicine</i> , 2022, 11, 3969-3981.	1.3	11
846	Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer. <i>Pharmacological Research</i> , 2022, 178, 106162.	3.1	40
847	Aptamer-drug conjugates: New probes for imaging and targeted therapy. <i>Biosensors and Bioelectronics</i> , 2022, 10, 100126.	0.9	3
848	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. <i>European Journal of Cancer</i> , 2022, 166, 87-99.	1.3	21
849	Are we ready to embrace novel therapeutic targets for women with AR-positive or AR-negative metastatic Triple-Negative Breast Cancer?. <i>Asia-Pacific Journal of Oncology</i> , 2021, , .	0.2	0

#	ARTICLE	IF	CITATIONS
850	Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 482-490.	1.0	0
851	With Our Powers Combined. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 511-520.	1.0	1
852	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	6
853	Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report. <i>Journal of Molecular Pathology</i> , 2021, 2, 319-324.	0.5	0
854	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. <i>Cancers</i> , 2021, 13, 6385.	1.7	19
855	Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome. <i>Scientific Reports</i> , 2021, 11, 23429.	1.6	1
857	Peculiarities of BRCA1/2 testing in patients with advanced HER2-negative breast cancer in the Russian Federation (results of a survey of Russian oncologists). <i>Malignant Tumours</i> , 2021, 11, 38-44.	0.1	0
858	Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 790967.	1.3	2
859	The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. <i>Journal of Hematology and Oncology</i> , 2021, 14, 206.	6.9	24
860	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 141-153.	1.1	5
861	Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 60-78.	1.0	5
862	PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?. <i>Ecancermedalscience</i> , 2021, 15, ed118.	0.6	4
863	Real-World Outcome of Platinum-Based Chemotherapy in Advanced Breast Cancer (ABC): A Retrospective Study from a Tertiary Cancer Center in India. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
864	Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 1270.	1.7	5
865	Current state of clinical development of TROP2-directed antibody-drug conjugates for triple-negative breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 129-132.	0.3	3
866	Triple negative breast cancer: any closer to cracking the code?. <i>Current Opinion in Obstetrics and Gynecology</i> , 2022, 34, 52-55.	0.9	4
867	Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 23435.	1.6	10
868	Update Mammakarzinom 2021 Teil 1 â€“ PrÃvention und frÃhe Krankheitsstadien. <i>Senologie - Zeitschrift FÃr Mammadiagnostik Und -therapie</i> , 2021, 18, 377-390.	0.0	0

#	ARTICLE	IF	CITATIONS
869	Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 3133-3140.	0.6	2
870	Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. <i>Cancer Research</i> , 2022, 82, 1646-1657.	0.4	40
871	PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 607-631.	1.9	20
872	Tumor genetics and individualized therapy. <i>Der Gynakologe</i> , 0, , .	1.0	0
873	An Exposure-Response Model with Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial. <i>Journal of Clinical Pharmacology</i> , 2022, , .	1.0	3
875	Targeting mutations in cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	56
876	A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients. <i>Oral Oncology</i> , 2022, 128, 105860.	0.8	4
881	Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas. <i>Npj Precision Oncology</i> , 2022, 6, 29.	2.3	6
882	Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 633-644.	1.9	2
883	An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022, 48, 760-770.	0.7	2
884	A Phase I trial of talazoparib in patients with advanced hematologic malignancies. <i>International Journal of Hematologic Oncology</i> , 2021, 10, IJH35.	0.7	0
885	Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.. <i>American Journal of Cancer Research</i> , 2022, 12, 337-354.	1.4	0
886	DNA damage and metabolic mechanisms of cancer drug resistance. <i>Cancer Drug Resistance (Alhambra)</i> , Tj ETQq0 0,0 rgBT /Qverlock 10 0,9 7		
887	Targeting biologically specific molecules in triple negative breast cancer (TNBC)., 2022, , 177-200.		7
888	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. <i>Cancers</i> , 2022, 14, 2161.	1.7	15
890	DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. <i>Cells</i> , 2022, 11, 1463.	1.8	3
891	Development of 1-(4-(Substituted)piperazin-1-yl)-2-((4-methoxybenzyl)thio)pyrimidin-4-yl)oxy)ethanones That Target Poly (ADP-Ribose) Polymerase in Human Breast Cancer Cells. <i>Molecules</i> , 2022, 27, 2848.	1.7	5
892	Attitudes and training needs of oncologists and surgeons in mainstreaming breast cancer genetic counseling in a low-to-middle income Asian country. <i>Journal of Genetic Counseling</i> , 2022, 31, 1080-1089.	0.9	4

#	ARTICLE	IF	CITATIONS
893	Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer. <i>Advances in Oncology</i> , 2022, 2, 47-61.	0.1	2
894	Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland. <i>Prostate International</i> , 2022, 10, 142-147.	1.2	4
895	Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 235-240.	1.5	6
896	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 64.	2.3	3
897	Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 113-123.	1.0	10
899	Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies. <i>BioNanoScience</i> , 2022, 12, 1404-1435.	1.5	2
900	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
901	Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
902	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	2.0	26
903	Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. <i>Cancer Treatment Reviews</i> , 2022, 108, 102417.	3.4	11
904	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 47-59.	1.8	8
905	The History of Early Breast Cancer Treatment. <i>Genes</i> , 2022, 13, 960.	1.0	16
906	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	68
907	Breast Cancer–Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). <i>Cancers</i> , 2022, 14, 2569.	1.7	94
908	Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	14
909	Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. <i>Cancer Letters</i> , 2022, 547, 215775.	3.2	7
910	Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	3
911	Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. <i>Oncogene</i> , 2022, 41, 3498-3506.	2.6	9

#	ARTICLE	IF	CITATIONS
912	Talazoparib in <i>BRCA</i> -mutated advanced breast cancer: is it earlier better?. <i>Pharmacogenomics</i> , 2022, 23, 487-492.	0.6	0
914	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 71, 128821.	1.0	8
915	Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 560-76.	0.9	3
916	Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. <i>NAR Cancer</i> , 2022, 4, .	1.6	10
917	Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 808-824.	1.8	2
918	Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. <i>Targeted Oncology</i> , 2022, 17, 355-368.	1.7	1
919	Chemotherapy Regimens Received by Women with <i>BRCA1/2</i> Pathogenic Variants for Early-Stage Breast Cancer Treatment. <i>JNCI Cancer Spectrum</i> , 0, , .	1.4	0
920	Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
922	The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 723-734.	2.3	19
923	Breast Cancer Genomics: Primary and Most Common Metastases. <i>Cancers</i> , 2022, 14, 3046.	1.7	3
924	Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
925	Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary <i>BRCA</i> Mutation. <i>Clinical Cancer Research</i> , 2022, 28, 3669-3676.	3.2	3
926	Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer. <i>Journal of Investigative Medicine</i> , 2022, 70, 1329-1341.	0.7	2
927	PARP Inhibitors: A New Horizon for Patients with Prostate Cancer. <i>Biomedicines</i> , 2022, 10, 1416.	1.4	20
928	In situ Injection of pH- and Temperature-Sensitive Nanomaterials Increases Chemo-Photothermal Efficacy by Alleviating the Tumor Immunosuppressive Microenvironment. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 2661-2678.	3.3	3
929	Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer. <i>Journal of Cellular and Molecular Medicine</i> , 0, , .	1.6	1
930	Circulating tumor DNA: current challenges for clinical utility. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	50
931	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 461-481.	0.6	6

#	ARTICLE	IF	CITATIONS
932	Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation. <i>Cancer Research and Treatment</i> , 2023, 55, 155-166.	1.3	1
933	Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer. <i>Meditsinskiy Sovet</i> , 2022, , 179-184.	0.1	0
934	Hematological disorders after salvage <sc>PARPi</sc> treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes. <i>International Journal of Cancer</i> , 2022, 151, 1791-1803.	2.3	7
935	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. <i>Cancers</i> , 2022, 14, 2950.	1.7	9
936	Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. <i>Breast</i> , 2022, 65, 32-40.	0.9	25
937	Cancer treatment and survivorship statistics, 2022. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 409-436.	157.7	897
938	Germline Mutations in Patients With Early-Onset Prostate Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
939	Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 557-573.	1.5	5
941	Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2022, 16, 117822342211075.	0.6	2
942	Genetic Screens Reveal New Targetable Vulnerabilities in BAP1-Deficient Mesothelioma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
943	Molecular Mechanisms of Parthanatos and Its Role in Diverse Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7292.	1.8	31
944	The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point. <i>Pathology</i> , 2022, , .	0.3	0
945	Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer. <i>Cancers</i> , 2022, 14, 3175.	1.7	6
946	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 3205-3221.	0.8	43
947	Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. <i>Journal of Market Access & Health Policy</i> , 2022, 10, .	0.8	2
948	Addressing the routine failure to clinically identify monogenic cases of common disease. <i>Genome Medicine</i> , 2022, 14, .	3.6	11
949	Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy Individuals. <i>Journal of Clinical Medicine</i> , 2022, 11, 3996.	1.0	4
950	Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation. <i>Cancers</i> , 2022, 14, 3266.	1.7	3

#	ARTICLE	IF	CITATIONS
951	Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. Expert Opinion on Investigational Drugs, 2022, 31, 855-874.	1.9	2
952	From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. Cancers, 2022, 14, 3469.	1.7	5
953	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2022, 33, 750-768.	0.6	204
954	Reconsidering the mechanisms of action of <sc>PARP</sc> inhibitors based on clinical outcomes. Cancer Science, 2022, 113, 2943-2951.	1.7	11
955	Characteristics of breast cancer patients tested for germline <i>BRCA1/2</i> mutations by next-generation sequencing in Ramathibodi Hospital, Mahidol University. Cancer Reports, 2023, 6, .	0.6	4
956	Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management. International Journal of Molecular Sciences, 2022, 23, 7481.	1.8	12
957	Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer. Current Oncology, 2022, 29, 4748-4767.	0.9	9
958	Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review. Frontiers in Pharmacology, 0, 13, .	1.6	1
959	Breast cancer brain metastasis: Current evidence and future directions. Cancer Medicine, 2023, 12, 1007-1024.	1.3	18
960	Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma. Communications Medicine, 2022, 2, .	1.9	5
961	A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers. Frontiers in Pharmacology, 0, 13, .	1.6	1
962	Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 1-15.	1.1	19
963	Leptomeningeal Metastases: New Opportunities in the Modern Era. Neurotherapeutics, 2022, 19, 1782-1798.	2.1	9
964	Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants. OncoTargets and Therapy, 0, Volume 15, 815-826.	1.0	4
965	Current State of Cell Therapies for Breast Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 301-309.	1.0	5
966	PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications. Biomedicine and Pharmacotherapy, 2022, 153, 113458.	2.5	5
967	Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. , 2022, 237, 108253.		52
968	Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study. Breast Cancer, 2022, 29, 1088-1098.	1.3	3

#	ARTICLE	IF	CITATIONS
969	Hematological toxicities in <sc>PARP</sc> inhibitors: A real-world study using <sc>FDA</sc> adverse event reporting system (<sc>FAERS</sc>) database. <i>Cancer Medicine</i> , 2023, 12, 3365-3375.	1.3	18
970	PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8412.	1.8	19
971	Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything. <i>Cancers</i> , 2022, 14, 3729.	1.7	5
972	Functional roles of ADP-ribosylation writers, readers and erasers. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	6
973	Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors. <i>International Journal of Toxicology</i> , 0, , 109158182211213.	0.6	0
974	Marker assessments in <sc>ER</sc>-positive breast cancers: old markers, new applications?. <i>Histopathology</i> , 2023, 82, 218-231.	1.6	3
975	Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. <i>Biomarkers</i> , 2022, 27, 764-772.	0.9	5
976	Mutational landscape of homologous recombination-related genes in small-cell lung cancer. <i>Cancer Medicine</i> , 2023, 12, 4486-4495.	1.3	5
979	Triple negative breast cancer: approved treatment options and their mechanisms of action. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3701-3719.	1.2	13
980	Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
981	Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 243-252.	1.0	1
982	Impact of <i>BRCA1/2</i> cascade testing on anxiety, depression, and cancer worry levels among unaffected relatives in a multiethnic Asian cohort. <i>Journal of Genetic Counseling</i> , 0, , .	0.9	0
984	Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board. <i>Oncologist</i> , 2023, 28, 33-39.	1.9	2
985	Triple negative breast cancer: Pitfalls and progress. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	110
986	ESOâ€ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). <i>Annals of Oncology</i> , 2022, 33, 1097-1118.	0.6	46
987	Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. <i>Cancers</i> , 2022, 14, 4064.	1.7	11
988	A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland. <i>Familial Cancer</i> , 2023, 22, 135-149.	0.9	2
989	Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancerâ€A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9

#	ARTICLE	IF	CITATIONS
990	Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1343-1360.	0.5	3
991	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 597-617.	2.7	6
992	Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. <i>EClinicalMedicine</i> , 2022, 52, 101595.	3.2	14
993	Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. <i>Breast</i> , 2022, 65, 145-150.	0.9	6
994	Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?. <i>Cancer Treatment Reviews</i> , 2022, 110, 102459.	3.4	9
996	Targeting cancer stem cells in the tumor microenvironment: An emerging role of PARP inhibitors. <i>Pharmacological Research</i> , 2022, 184, 106425.	3.1	10
997	Chapter 21: Oncology: Rasburicase/ <i>G6PD</i> Case. , 2022, , .		0
999	Chapter 29: Pharmacogenomics in Ethical and Social Contexts. , 2022, , .		0
1001	Chapter 27: Rheumatology/Musculoskeletal Pain: Codeine/ <i>CYP2D6</i> Case. , 2022, , .		0
1002	Chapter 8: Cardiology: Simvastatin/ <i>SLCO1B1</i> Case. , 2022, , .		0
1003	Chapter 28: Information Resources for Pharmacogenomics. , 2022, , .		0
1004	Chapter 18: Oncology: Somatic Disease and Pharmacogenomics. , 2022, , .		0
1005	Chapter 17: Neurology: Fosphenytoin/Phenytoin/ <i>CYP2C9</i> , <i>HLA-B</i> Case. , 2022, , .		0
1006	Chapter 9: Cardiology: Warfarin/ <i>CYP2C9</i> , <i>VKORC1</i> , <i>CYP4F2</i> Case. , 2022, , .		0
1007	Chapter 25: Rheumatology/Musculoskeletal Pain: Allopurinol/ <i>HLA-B</i> Case. , 2022, , .		0
1008	Chapter 12: Infectious Diseases: Abacavir/ <i>HLA-B</i> Case. , 2022, , .		0
1009	Chapter 15: Infectious Diseases: Gentamicin/ <i>MT-RNR1</i> Case. , 2022, , .		0
1011	Chapter 13: Infectious Diseases: Atazanavir/ <i>UGT1A1</i> Case. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
1012	Chapter 30: Pharmacogenomics and Secondary/Incidental Findings. , 2022, , .		0
1013	Chapter 16: Neurology: Carbamazepine/<i>HLA-A</i>, <i>HLA-B</i> Case. , 2022, , .		0
1015	Chapter 3: Pharmacogenomics Testing. , 2022, , .		0
1016	Chapter 24: Metabolic/Respiratory: Ivacaftor/<i>CFTR</i> Case. , 2022, , .		0
1017	Chapter 23: Psychiatry: Paroxetine/<i>CYP2D6</i> Case. , 2022, , .		0
1019	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2022, , .		0
1020	Chapter 22: Psychiatry: Amitriptyline/<i>CYP2C19</i>, <i>CYP2D6</i> Case. , 2022, , .		0
1021	Chapter 6: The Pharmacists' Patient Care Process (PPCP). , 2022, , .		0
1022	The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. <i>Cancers</i> , 2022, 14, 4203.	1.7	5
1023	The pathological and clinical landscape of refractory metastatic triple negative breast cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 907-907.	0.7	1
1024	Chapter 10: Endocrinology: Glipizide/<i>G6PD</i> Case. , 2022, , .		0
1025	Chapter 1: Foundations of Pharmacogenomics. , 2022, , .		0
1026	Chapter 20: Oncology: Capecitabine/<i>DPYD</i> Case. , 2022, , .		0
1028	Chapter 14: Infectious Diseases: Voriconazole/<i>CYP2C19</i> Case. , 2022, , .		0
1029	Chapter 19: Oncology: Mercaptopurine/<i>TPMT</i>, <i>NUDT15</i> Case. , 2022, , .		0
1030	Chapter 7: Cardiology: Clopidogrel/<i>CYP2C19</i> Case. , 2022, , .		0
1031	Chapter 4: Pharmacists' Competencies in Genomics. , 2022, , .		0
1033	Chapter 5: Implementation of Pharmacogenomics across Practice Settings. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
1034	Chapter 26: Rheumatology/Musculoskeletal Pain: Azathioprine/ <i>TPMT</i> , <i>NUDT15</i> ; Celecoxib/ <i>CYP2C9</i> Case. , 2022, , .		0
1035	Chapter 11: Immunology: Tacrolimus/ <i>CYP3A5</i> Case. , 2022, , .		0
1037	Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, .	0.6	5
1038	Survival outcomes of metastatic breast cancer patients by germline <i>BRCA1/2</i> status in a large multicenter real-world database. <i>International Journal of Cancer</i> , 2023, 152, 921-931.	2.3	3
1039	Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfILER-01 Trial. <i>Journal of Personalized Medicine</i> , 2022, 12, 1595.	1.1	3
1040	Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome. <i>Cancers</i> , 2022, 14, 4717.	1.7	1
1042	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	35
1043	Targeted Sequencing of Germline Breast Cancer Susceptibility Genes for Discovering Pathogenic/Likely Pathogenic Variants in the Jakarta Population. <i>Diagnostics</i> , 2022, 12, 2241.	1.3	0
1044	Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 705-712.	0.2	0
1045	Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	5
1046	Breast cancer: an update review and future perspectives. <i>Cancer Communications</i> , 2022, 42, 913-936.	3.7	70
1047	Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer. <i>JAMA Network Open</i> , 2022, 5, e2232787.	2.8	10
1049	Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. <i>Future Oncology</i> , 2022, 18, 3701-3711.	1.1	3
1050	Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 40-49.	3.2	3
1051	Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1457-1476.	1.3	1
1052	Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors. <i>PLoS ONE</i> , 2022, 17, e0272065.	1.1	3
1053	A two-step mechanism governing PARP1-DNA retention by PARP inhibitors. <i>Science Advances</i> , 2022, 8, .	4.7	13
1054	Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer. <i>Current Oncology</i> , 2022, 29, 6847-6863.	0.9	7

#	ARTICLE	IF	CITATIONS
1055	PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. <i>Cancers</i> , 2022, 14, 4332.	1.7	17
1056	Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. <i>Oncologist</i> , 2022, 27, e783-e795.	1.9	5
1057	Targeting the DNA damage response in pediatric malignancies. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-15.	1.1	0
1059	Emerging Targeted Therapies for Early Breast Cancer. <i>Drugs</i> , 2022, 82, 1437-1451.	4.9	5
1060	Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 111, 102468.	3.4	10
1062	Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2â€™Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel. <i>Breast</i> , 2022, 66, 236-244.	0.9	1
1063	Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy. <i>Pharmacological Research</i> , 2022, 186, 106529.	3.1	13
1064	Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1801-1819.	1.8	7
1065	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
1066	The Present and Future of Clinical Management in Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5891.	1.0	7
1067	Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	9
1068	A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. <i>Nature Cancer</i> , 2022, 3, 1181-1191.	5.7	42
1069	Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 4829.	1.7	8
1071	Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications. <i>Current Oncology Reports</i> , 2022, 24, 1791-1800.	1.8	1
1072	Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1649-1675.	1.6	23
1073	Advances in the Management of Central Nervous System Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12525.	1.8	1
1074	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
1075	Subpathway Analysis of Transcriptome Profiles Reveals New Molecular Mechanisms of Acquired Chemotherapy Resistance in Breast Cancer. <i>Cancers</i> , 2022, 14, 4878.	1.7	4

#	ARTICLE	IF	CITATIONS
1076	Breast cancer liver metastasis: time to resection and criteria. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 749-751.	0.7	1
1077	PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. <i>Breast</i> , 2022, 66, 293-304.	0.9	4
1078	Viral protein engagement of GBF1 induces host cell vulnerability through synthetic lethality. <i>Journal of Cell Biology</i> , 2022, 221, .	2.3	6
1079	Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. <i>Nature Cancer</i> , 2022, 3, 1211-1227.	5.7	7
1080	Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists' Perspective. <i>Journal of Clinical Medicine</i> , 2022, 11, 6021.	1.0	2
1081	Expanding biomarkers for PARP inhibitors. <i>Nature Cancer</i> , 2022, 3, 1141-1143.	5.7	2
1082	Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. <i>Annals of Oncology</i> , 2022, 33, 1250-1268.	0.6	128
1083	BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling. <i>Nature Communications</i> , 2022, 13, .	5.8	22
1084	Genetics of Breast Cancer. <i>Surgical Clinics of North America</i> , 2022, , .	0.5	5
1086	Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103848.	2.0	4
1087	Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer. <i>Biomedicines</i> , 2022, 10, 2775.	1.4	5
1088	Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. <i>European Journal of Cancer</i> , 2023, 179, 136-146.	1.3	13
1089	Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?. <i>JCO Precision Oncology</i> , 2022, , .	1.5	0
1090	Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1765-1770.	0.9	1
1091	BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel. <i>Cancers</i> , 2022, 14, 5399.	1.7	2
1092	Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer. <i>JAMA Network Open</i> , 2022, 5, e2239788.	2.8	8
1093	Exploring the DNA damage response pathway for synthetic lethality. <i>Genome Instability & Disease</i> , 2023, 4, 98-120.	0.5	2
1094	Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1399-1413.	1.3	3

#	ARTICLE	IF	CITATIONS
1095	Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 51-56.	1.1	3
1096	Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer in the United States, Europe, and Israel. <i>Advances in Therapy</i> , 2023, 40, 331-348.	1.3	4
1097	Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response. <i>Anticancer Research</i> , 2022, 42, 5257-5263.	0.5	0
1099	BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy. <i>Cancers</i> , 2022, 14, 5619.	1.7	3
1100	Development of a novel BRCAness score that predicts response to PARP inhibitors. <i>Biomarker Research</i> , 2022, 10, .	2.8	6
1101	Interactive effects of molecular subtypes with tumor size and extracranial metastatic pattern on risk of brain metastasis in breast cancer patients: A population-based study. <i>Cancer Medicine</i> , 2023, 12, 6547-6557.	1.3	1
1102	Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. <i>International Immunopharmacology</i> , 2022, 113, 109444.	1.7	6
1103	Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2023, 9, 40.	3.4	22
1104	Combining PARP Inhibitor With Immunotherapy—Does the Promise of Preclinical Data Translate to Clinic?. <i>JAMA Oncology</i> , 0, , .	3.4	1
1105	Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors. <i>JAMA Oncology</i> , 2023, 9, 29.	3.4	21
1106	Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints. <i>Cancers</i> , 2022, 14, 5633.	1.7	6
1107	Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	4
1108	PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer. <i>European Medical Journal Oncology</i> , 0, , 68-76.	0.0	1
1109	Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 152.	0.1	1
1110	Current Standard Clinical Predictive Markers. , 2022, , 873-894.		0
1111	Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer. , 2023, 241, 108331.		2
1112	Testing for Inherited Susceptibility to Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 17-31.	0.9	0
1113	Breast Cancer Pathology in the Era of Genomics. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 33-50.	0.9	2

#	ARTICLE	IF	CITATIONS
1114	Systemic Therapy for Hereditary Breast Cancers. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 203-224.	0.9	1
1115	Triple-Negative/Basal-Like Breast Carcinomas. , 2022, , 445-462.		0
1116	Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 98.	0.1	1
1117	Principalele abordări de profilare moleculară în oncologie: tehnologie, avantaje și limitări. <i>Oncolog-Hematolog Ro</i> , 2022, 4, 34.	0.0	0
1118	Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
1120	DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14672.	1.8	26
1121	Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. <i>Cancers</i> , 2022, 14, 5795.	1.7	4
1123	Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1686-1698.	5.7	1
1124	The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1203-1226.	1.9	1
1125	Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. <i>PLoS ONE</i> , 2022, 17, e0279286.	1.1	1
1126	Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research™. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1291-1310.	1.9	2
1127	Hereditary breast cancer: syndromes, tumour pathology and molecular testing. <i>Histopathology</i> , 2023, 82, 70-82.	1.6	18
1128	Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 489-501.	1.1	5
1129	Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. <i>PLoS ONE</i> , 2022, 17, e0278460.	1.1	1
1130	Therapy of BRCA-associated metastatic breast cancer. Efficacy and safety of talazoparib in the real-world clinical practice. <i>Meditinskiy Sovet</i> , 2022, , 21-29.	0.1	0
1131	Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine in patients with advanced triple-negative breast cancer: a monocentric, retrospective comparison. <i>Clinical Breast Cancer</i> , 2022, , .	1.1	4
1132	The BRCAness Landscape of Cancer. <i>Cells</i> , 2022, 11, 3877.	1.8	5
1133	Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?. <i>Current Breast Cancer Reports</i> , 0, , .	0.5	0

#	ARTICLE	IF	CITATIONS
1134	Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 207.	1.8	1
1135	Neurologic complications of breast cancer. <i>Cancer</i> , 0, , .	2.0	0
1136	Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 31-49.	0.6	1
1137	Targeting DNA damage response pathways in cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 78-94.	12.8	158
1138	Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms. <i>Archives of Medical Research</i> , 2022, 53, 807-817.	1.5	1
1139	Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial. <i>Health Psychology and Behavioral Medicine</i> , 2022, 10, 1190-1215.	0.8	0
1140	Evolving DNA repair synthetic lethality targets in cancer. <i>Bioscience Reports</i> , 2022, 42, .	1.1	3
1141	IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
1142	Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2 "negative advanced breast cancer from the United States, Europe, and Israel. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
1143	Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2023, 24, 162-174.	5.1	20
1144	Breast cancer heterogeneity and its implication in personalized precision therapy. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	31
1145	How I treat HER2-low advanced breast cancer. <i>Breast</i> , 2023, 67, 116-123.	0.9	5
1147	Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. <i>Cell Reports Medicine</i> , 2023, 4, 100915.	3.3	5
1148	Theranostics for Triple-Negative Breast Cancer. <i>Diagnostics</i> , 2023, 13, 272.	1.3	7
1149	Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study. <i>Journal of Medical Genetics</i> , 2023, 60, 760-768.	1.5	3
1150	Systemic treatments for breast cancer brain metastasis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1151	A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer. <i>Cancer Letters</i> , 2023, 555, 216049.	3.2	4
1152	Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review. <i>Cancer Treatment Reviews</i> , 2023, 114, 102511.	3.4	4

#	ARTICLE	IF	CITATIONS
1153	Crystal structure, in silico molecular docking, DFT analysis and ADMET studies of N-(2-methoxy-benzyl)-acetamide. <i>European Journal of Chemistry</i> , 2022, 13, 440-450.	0.3	2
1154	Cancer risk-reducing surgery: Brazilian Society of Surgical Oncology Guideline Part 2 (Gastrointestinal and thyroid). <i>Journal of Surgical Oncology</i> , 2022, 126, 20-27.	0.8	1
1155	Triple-Negative Breast Cancer Therapy: Recent Advances, Challenges, and Future Perspective. , 2023, , .		0
1156	The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-8.	1.1	0
1158	SUMOylation of HNRNPA2B1 modulates RPA dynamics during unperturbed replication and genotoxic stress responses. <i>Molecular Cell</i> , 2023, 83, 539-555.e7.	4.5	8
1159	Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
1160	Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. <i>Annals of Oncology</i> , 2023, 34, 397-409.	0.6	10
1161	What is precision medicine in oncology?. , 2023, , 1-30.		0
1162	Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA. <i>Cancer Research and Treatment</i> , 2023, 55, 1048-1052.	1.3	2
1163	The HER2-low revolution in breast oncology: steps forward and emerging challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311528.	1.4	10
1165	Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
1166	Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211461.	1.4	5
1167	Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1168	Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 0, , .	1.9	0
1170	3D-QSAR, molecular docking, and molecular dynamics analysis of dihydrodiazaindalone derivatives as PARP-1 inhibitors. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	2
1171	Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy. <i>Cancers</i> , 2023, 15, 2194.	1.7	0
1172	Deciphering breast cancer: from biology to the clinic. <i>Cell</i> , 2023, 186, 1708-1728.	13.5	72
1173	Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. <i>British Journal of Cancer</i> , 2023, 128, 2072-2080.	2.9	0

#	ARTICLE	IF	CITATIONS
1174	Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer. <i>Breast</i> , 2023, 68, 173-180.	0.9	2
1175	Instant Oncology: OlympiAD. <i>Clinical Oncology</i> , 2023, 35, 329-330.	0.6	0
1176	A robust and lightweight deep attention multiple instance learning algorithm for predicting genetic alterations. <i>Computerized Medical Imaging and Graphics</i> , 2023, 105, 102189.	3.5	2
1177	Cancer risk—reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and) Tj ETQq1 1 0.784314 rgBT /Over	0.8	1
1178	Mild photothermal therapy boosts nanomedicine antitumor efficacy by disrupting DNA damage repair pathways and modulating tumor mechanics. <i>Nano Today</i> , 2023, 49, 101767.	6.2	20
1179	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. <i>Biology</i> , 2023, 12, 218.	1.3	27
1180	PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 91, 203-217.	1.1	3
1181	Metastatic Breast Cancer to the Spine: Incidence of Somatic Gene Alterations and Association of Targeted Therapies With Overall Survival. <i>Neurosurgery</i> , 2023, 92, 1183-1191.	0.6	0
1182	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. <i>Cancers</i> , 2023, 15, 1093.	1.7	4
1183	Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow. <i>Journal of Clinical Oncology</i> , 2023, 41, 2767-2778.	0.8	5
1184	Prediction of carrying a BRCA1 or BRCA2 mutation. <i>Annals of Translational Medicine</i> , 2023, 11, 271-271.	0.7	1
1185	Efficacy and safety of treatment regimens for patients with metastatic, locally advanced, or recurrent breast cancer carrying BRCA1/BRCA2 pathogenic variants: A network meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1186	Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). <i>Journal of Clinical Medicine</i> , 2023, 12, 1524.	1.0	11
1187	Anticancer Effects of Propolis Extracts Obtained Using the Cold Separation Method on Breast Cancer Cell Lines. <i>Plants</i> , 2023, 12, 884.	1.6	0
1188	Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 333-342.	1.9	2
1189	How I treat endocrine-dependent metastatic breast cancer. <i>ESMO Open</i> , 2023, 8, 100882.	2.0	6
1190	Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. <i>Cancers</i> , 2023, 15, 1299.	1.7	5
1191	Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3

#	ARTICLE	IF	CITATIONS
1211	Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead. Current Treatment Options in Oncology, 2023, 24, 442-465.	1.3	6
1212	Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer. British Journal of Cancer, 2023, 128, 1964-1975.	2.9	4
1213	Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. International Journal of Cancer, 2023, 153, 803-814.	2.3	4
1214	Aptamer-Based Strategies to Boost Immunotherapy in TNBC. Cancers, 2023, 15, 2010.	1.7	5
1215	Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. Cancers, 2023, 15, 2015.	1.7	3
1216	Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis. Breast Cancer Research and Treatment, 0, , .	1.1	0
1217	Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. Current Oncology Reports, 2023, 25, 689-698.	1.8	2
1218	Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 351-358.e4.	2.3	3
1219	A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA). ESMO Open, 2023, 8, 101207.	2.0	0
1220	Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC). Drug Development Research, 2023, 84, 629-653.	1.4	3
1221	Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer. Expert Opinion on Pharmacotherapy, 2023, 24, 789-801.	0.9	1
1222	Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. Cancers, 2023, 15, 2204.	1.7	10
1223	Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer. Journal of Cellular Physiology, 0, , .	2.0	0
1224	Complete Response Following Treatment with Olaparib in a Patient with BRCA-Mutant High-Grade Serous Ovarian Cancer and Central Nervous System Metastases. Indian Journal of Gynecologic Oncology, 2023, 21, .	0.1	0
1226	PARP Inhibitors in Breast and Ovarian Cancer. Cancers, 2023, 15, 2357.	1.7	9
1227	Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer. Clinical and Translational Oncology, 0, , .	1.2	0
1228	Targeted therapy. , 2023, , 205-411.		0
1229	Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge. Npj Precision Oncology, 2023, 7, .	2.3	1

#	ARTICLE	IF	CITATIONS
1237	Clinical efficacy of PARP inhibitors in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 200, 15-22.	1.1	3
1241	Epigenetic profiling in cancer: triage, prognosis, and precision oncology. , 2023, , 651-674.		0
1265	DNA repair pathways in breast cancer: from mechanisms to clinical applications. <i>Breast Cancer Research and Treatment</i> , 2023, 200, 305-321.	1.1	2
1308	A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1- Δ 11q splice variant. <i>Oncogene</i> , 0, , .	2.6	1
1323	Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	4
1327	The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer. <i>Oncology and Therapy</i> , 0, , .	1.0	0
1331	Molecular tumour boards " current and future considerations for precision oncology. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 843-863.	12.5	6
1333	Molecular testing in breast cancer. , 2024, , 303-318.		0
1346	Ovarian cancer treatment strategies: focus on PARP inhibitors. , 2023, , .		0
1350	Genetic Testing in Metastatic Breast Cancer in the USA: A Podcast. <i>Oncology and Therapy</i> , 0, , .	1.0	1
1376	Emerging treatment approaches for triple-negative breast cancer. , 2024, 41, .		1
1379	Exploring the therapeutic potential of ADC combination for triple-negative breast cancer. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	0
1380	Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers. <i>Cancer Treatment and Research</i> , 2023, , 207-221.	0.2	0
1386	Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges. <i>Cancer Treatment and Research</i> , 2023, , 143-170.	0.2	0
1387	Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer. <i>Cancer Treatment and Research</i> , 2023, , 91-102.	0.2	0
1400	Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy. , 2024, 41, .		1
1401	Handling Germline Findings in Ovarian Cancer Cases. , 2023, , 129-141.		0
1410	A Closer Look at the Androgen Receptor (AR)- positive and AR-negative Metastatic Triple-Negative Breast Cancer: Can We Apply Novel Targeted Therapeutics?. , 2023, , 22-38.		0

#	ARTICLE	IF	CITATIONS
1411	Can We Find A Noninvasive Tool of Precision Medicine That Can Always Be Used For the Individualized Treatment of Women With Breast Cancer?. , 2023, , 96-107.		0
1427	Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer. Cancer Treatment and Research, 2023, , 1-27.	0.2	0
1428	New Concepts in Cardio-Oncology. Cancer Treatment and Research, 2023, , 303-341.	0.2	0
1429	Breast Cancer Brain Metastases: Achilles' Heel in Breast Cancer Patients' Care. Cancer Treatment and Research, 2023, , 283-302.	0.2	0
1441	Pharmacogenomics and oncology: A therapeutic approach for cancer treatment. , 2024, , 223-243.		0